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Introduction: Neuroendocrine tumors are known to overexpress somatostatin receptors. 
Radiolabeled stable somatostatin analogs are clinically used for the diagnosis and 
radionuclide therapy of neuroendocrine tumors. However, because the radiolabeled 
somatostatin analogs such as 111In-DTPA-D-Phe1-octreotide (D-Phe(1)) show a high and 
prolonged radioactivity in the kidneys, this undesirable radiation exposure leads to 
diagnostic inaccuracy and nephrotoxicity. Therefore, reducing kidney radioactivity 
levels is clinically urgent and important. To resolve this issue, the author designed 111In-
DTPA- D-Phe1-octreotide derivatives based on a chemical modification of the peptide 
sequence by introducing a negatively charged acidic amino acid such as L-aspartic acid 
(Asp) to induce electrostatic repulsion toward the negatively charged renal cell surface.  
Methods: The tumor accumulation of octreotide derivatives was determined by 
measuring its uptake using AR42J somatostatin receptor expression cells in vitro and in 
vivo. The renal radioacitivity levels after administration of the peptides were evaluated 
by a counting method using normal or tumor-bearing mice. In addition, the radioactive 
metabolite species in the kidney and tumor were identified by HPLC analyses.  
Results: As negatively charged peptides, 111In-DTPA-Asp1-octreotide (Asp(1)), 111In-
DTPA-Asp0-D-Phe1-octreotide (Asp(0)) and 111In-DTPA-D-Phe−1-Asp0-D-Phe1-
octreotide (D-Phe(−1)) were synthesized and evaluated for renal accumulation and 
tumor uptake by comparison with D-Phe(1) in biodistribution studies. The tumor uptake 
of Asp(1) was decreased sharply by replacement of N-terminal D-Phe of D-Phe(1). 
Asp(0), which contains additional Asp between the DTPA and D-Phe of D-Phe(1), was 
successful in reducing renal radioactivity levels at early post-injection times without 
decreasing its inherent binding affinity. However, at a later post-injection time, it 
exhibited significantly higher radioactivity level in the kidney than that of D-Phe(1).  
Considering previous study results, the new radiopeptide D-Phe(−1), where additional 
D-Phe is introduced between the DTPA and N-terminal Asp of Asp(0), was supposed to 
provide a renal lipophilic radiometabolite and shorten residence time of radioactivity in 
the kidney.  As expected, D-Phe(−1) exhibited reduction of renal radioactivity at both 
early and late stages after injection. In radiometabolite analysis, D-Phe(−1) was degraded 
to 111In-DTPA-D-Phe-OH as the final metabolite via 111In-DTPA-D-Phe-Asp-OH in the 
kidney. The analysis of urine samples indicated that 111In-DTPA-D-Phe-Asp-OH was 
preferentially excreted in urine compared with 111In-DTPA-D-Phe-OH. 
Furthermore, D-Phe(−1) demonstrated excellent targeting properties, that is, 
increasing the accumulation and persistence of tumor radioactivity for a prolonged 
period time. Although the detailed tumor accumulation mechanism of the peptide is 
remained unclear, it was indicated that additional D-Phe to the N-terminal of 111In-DTPA-
conjugated octreotide could efficiently internalize radioactivity into tumor cells, 
probably via receptor-mediated endocytotic processes in the peptide uptake. The 
persistence of tumor radioactivity for a prolonged duration may be ascribed to the slow 
metabolism of this peptide. 
Conclusion: These findings indicate new possibilities that the chemical modification of 
111In-DTPA-D-Phe1-octreotide provides one of the most successful approaches for 
developing radiopeptides that have a greater efficiency and safety for the diagnosis and 
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Fig. 1. Depiction of SPECT imaging (top) 
and PET imaging (bottom).5) 
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Fig. 2. Targeting overexpressed cell surface receptors in cancerous cells with 
radiopharamaceuticals.5) 
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Fig. 3. Chemical structure of 111In-DTPA-D-Phe1-octreotide. 
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Fig. 4. Imaging of 111In-DTPA-D-Phe1-octreotide study. White arrows on anterior and 
posterior image indicate a primary gastrinoma and a liver metastasis respectively .26)  
 
 
 ěâă octreotide ǅã7",, Ó!ěâăXVJNƯ !ƦǸƁĻĸ




ř	dHHi^ Ǯħǰ ő2ŖŨ3 (Fig. 5).27,28)  
 
 
Fig. 5. Proposal 111In-DTPA-D-Phe1-octreotide metabolism in kidney. 
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 Akizawa 0$ Arano 1", 111In-DTPA-D-Phe1-octreotide %¦Ùȃ7ġ
× ǌǺƮ7yo4#, XVJN	æƑƇƑƤƳǽ!ǌǺƮǻǺ¬
űƦǸƁ7đı3!"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DTPA-Asp1-octreotide, 111In-DTPA-D-Glu1-octreotide  0 $  111In-DTPA-(g-
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41ǅãĒoý!\<GƦǸƁ" 111In-DTPA-D-Phe1-octreotide
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Ť14
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Fig. 6. Proposal mechanism of inhibition of radiolabeled peptide reuptake to tubular cell 
by alteration of molecular charge. 
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 , û1" ddY \<G ƦǸƁ!Ő "ċ¢-!!, 
41XVJN!ƧůǸƁ "Ķƾ1, N įƄ:]QǨ!ƞę	
Ƨů%!ŚũŲǸƁ «(úǾƆ "Ħ1 .  
 , İŷƂ"ƦǸƁ7ŐƧůǸƁ7ƗĔěâă octreotide ǅ
ã!ǯű 02, NET !ǀĞƋõ!¶l0$Ú¤ĲŲŘâŰŊ!
Üş ǍŜ3,, Asp ãǌǺƮ7yo 111In-DTPA-octreotide ǅã
7²ċ, 41! in vitro 0$ in vivo ƧůǸƁă¥ĉ7ǁ
3. 
 ƅ  1 ƃ" , 111In-DTPA-D-Phe1-octreotide !XVJNǭ  N įƄ  D-Phe 7
Asp  ƞę 111In-DTPA-Asp1-octreotide 0$ N įƄ D-Phe 7!))
 , Asp 7XVJNǭ  N įƄ%}Ǯy£  111In-DTPA-Asp0-D-Phe1-
octreotide !²ċ0$Ƨůžĵ`Le\<G!ì ǈǜ3.  
 ƅ 2 ƃ", ƅ 1 ƃþ14ŵƸ7Ê , 111In-DTPA-D-Phe1-octreotide ! 
N įƄ% D-Phe-Asp ! 2 ŀÊ7}Ǯy£ğěâă octreotide ǅã 
111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide !²ċ0$ ddY \<G!
ì ǈǜ3.  
 ƅ  3 ƃ"  ƅ  2 ƃ²ċ  111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide 
!ƧůǸƁă , ÉȄƑƤ0$Ƨůžĵ`Le\<G 03ǁƔĲ
 ǃǜ3.  
  , İǈĝ"  111In-DTPA-D-Phe1-octreotide, 111In-DTPA-Asp1-octreotide, 
111In-DTPA-Asp0-D-Phe1-octreotide  0 $  111In-DTPA-D-Phe−1-Asp0-D-Phe1-
octreotide 744 D-Phe(1), Asp(1), Asp(0) 0$ D-Phe(−1) »Ž3. 
), Ś Ğ2!ǳ2İĝq! SSTR ", H\MGIJh¯ÞDUI








ĩ 1 Ĭ ôŚƉt DTPA ĶVTHL!ÍŒĔ 
 
 ¿řŢ%, , D-Phe(1) ! N éĨ D-Phe 3 Asp  ĺÙ Asp(1) 
-# , DTPA  N éĨ D-Phe !Ŷ  Asp 3¶| Asp(0) !Í3Œ
Ĕ (Fig. 7). 
 
 
Fig. 7. Chemical structures of target 111In-DTPA-octreotide derivatives. 
 
 111In ôŚƉt/ DTPA ĶVTHL!Í ", Fig. 8  Ġĉû 
DTPA (diethylentriaminepentaacetic dianhydride: cDTPA) 3VTHL! N éĨ6
YO¢$¶|/Îý	Ē-0
	,43) ª~  2 !ůĉûċòŧ
3å/)VTHLmªŶ!ªŶïöĶ!ÁÍ+,44,45) Tyr ø¢!
:DJ_Ķ!đÍ!É	ŨŊ,46) æ(/rĺ$!ŬÐę 








Ķ3ÁÍ  cDTPA 3Ē£ó!ĦtŮròŧ3h/ 1-tert-
butyl hydrogen 3,6,9-tris((tert-butoxycarbonyl)methyl)-3,6,9-triazaundecanoic acid (ť
ġ monoreactive DTPA; mDTPA, Fig. 8) 3ŵĘ. mDTPA " DTPA ! 5 !
=_W>B¢! 4 	 Boc ¢xś0, ĉxś!=_W>B¢3ÉĈ
 1 å., VTHL$!ŬÐę DTPA òŧ!¶|	ľ
	/. ¯Ż , !à DTPA ¶|ŕň mDTPA 3 DTPA-D-Phe1-octreotide 
!Í ÉĒ1, Æì!áý" 5% ģÀ}Íč3 32% 
 'f/ Í/.47,48)  
 Ňļ"Ã-!áý Æ, ôŚƉt DTPA-D-Phe1-octreotide, DTPA-
Asp1-octreotide ,# DTPA-Asp0-D-Phe1-octreotide !Í ", 00!V
THLŮ3 Fmoc ĜÍý 49) òĭÅ , mDTPA 3ĒűtÁÍ
ŭr3 N éĨ6YO¢$ŬÐę ¶|/áý3Ē/ (Fig. 9). 
 
 
Fig. 8. Chemical structures of DTPA, cDTPA and mDTPA. 
 
 




























ĩ 2 Ĭ ôŚƉt DTPA ĶVTHL!Í 
 
 ', Arano, Akizawa -!áý ÆűtÁÍŭr¶|!Ų/ mDTPA 
!Í ĝÎ (Scheme 1). C:H`bK^6Yb3 CF3CO2C2H5 Đ, 
éĨ6YO¢3 1 K^S_<a6EH_¢xś 1 3ŽĮŎ
/ BrCH2CO2t-Bu 3Ē6_>_ 2 . 2 3 DMF j, 
NaH  BrCH2CO2t-Bu 
	
 3 . Ç-0 3 !
K^S_<a6EH_¢3 t-BuOH j 100 eq. !ĉûQL]CbŸ, ķ
ƀ 2 ı6YO¢3 BrCH2CO2Bn Đ 4 . äÅ  4 !
UbC_¢3 Pd ő©« g, ×őûĲŸ, =_W>B¢	 1 
ũŽ mDTPA 3 4 Ŋģ 44% !čÍ. 
 
 
Scheme 1. Synthesis of mDTPA. 
 
 ÷ , VTHLų!Í3ŵ¨. Ěę!Ů3å/VTHLų" 2-?
aaK^H_õĿ3ĜÑt, Fmoc ý ,.òĭ/. ¼ŝ








    t-BuOH
    0 °C
2) BrCH2CO2Bn
    DIPEA, DMF












































2.5 eq. !zųxś Fmoc 6YOůŗ¶t3Ē, DIC ,# HOBt·H2O 3
 DMF j 1.5 ãŶÕÛÒ. N éĨ6YO¢$!6YOů!qŴ
"  Kaiser ŕƊ ,.ğŖ ,50) Fmoc ¢!Ÿ "  20% RV^Cbå 




Scheme 2. Synthesis of DTPA-D-Phe1-octreotide. 
 




1)  Fmoc-amino acid (2.5 eq.)
     DIC (2.5 eq.), HOBt·H2O (2.5 eq.)
resin

















HOBt·H2O 3Ē mDTPA 3¶|, ķõĿ3 2 eq. ! Tl(tfa)3 Đ
 Cys zųf! Acm ¢!Ÿ ķCD_S7LĶ3dÔ òĭ
.51,52) õĿ3 5% H<6NFc_3å/ TFA Đ, õĿ-!V
THL!.,#ůÌÊzųxś¢3Ÿ. ķţĜ HPLC 
!ĮŎ,#ĶlĊ3ĵĚę/ôŚƉtVTHL DTPA-D-Phe1-
octreotide 3 H-Thr(t-Bu)ol-ĶõĿ- 31% !čÇ. 'ó!áý
  DTPA-Asp1-octreotide ,#  DTPA-Asp0-D-Phe1-octreotide 3 , 00 
38% ,# 42% !čÇ.  
 Ç-0 DTPA-octreotide ŗ¶t (10 µg) ", ?:bůeMK^9Z (4.91 
mg), ?:bů (0.37 mg), 8OBKc_ (10.0 mg), @bHCbů (2.0 mg) 3
å/şİû!ąĀ (250 µL)  ąŐÅ ĶlĊ, 111In ôŚĒĶ
lĊ>IK300uŎ. , ĶlĊ>IKj!Ĥċ!ĴÍ
", ň¼ŝ0/ OctreoScan® ôŚ>IK!ĴÍ Æ.53) 
 
 
ĩ 3 Ĭ 111In-DTPA-octreotide ŗ¶t!ſúęÊŞ!Ŕw 
 
 >IKôŚƉtVTHL  111InCl3 (1.0−14.8 MBq) ! 0.02 N HCl 
ûąĀ3ā°ă 1 ãŶ8b>[UcKÅ, E_acD6EJcK
Ńſúþý,# TLC 3ĒĚę/ 111In ôŚVTHL D-Phe(1), 
Asp(1) ,# Asp(0) !Ýµ¬ęİÀ3Ą®. Ýµ¬ęİÀ!Ą®
", þÅ!E_acD6EJcKŃ,#ºŵÅ! TLC T`cK3d®!
Ŷźōß, Ç-0S]?B\b!Ýµľ3 NaI(Tl) BbH`cB\b
=9bGcĄ®/ī. !Ķî, }!VTHLÝµ¬
ęİÀ 95% of	Ŗ)-0, octreotide ! N éĨ D-Phe ! Asp $!ĺÙ 
(Asp(1)) -#  N éĨ  D-Phe  ´/  Asp !qŴn  (Asp(0)) 	 
DTPA !űÁÍľ ÂƄ3&	ğŖ0. 
 ¶| Asp  ,ª}t Ŝſņ	nh0/3ğŖ/
) , įďt1ŪÅ!¹,#ŉĀ! pH  ´É/ pH 5.0, 6.0, 7.0 ,# 
7.4 !^bůĹŋĀ3ĒE_acD6EJcKŃſúþý3¯â,  
 14 
111In ôŚVTHL!ſúęÊŞ3Ŕw. ÷VcC! Fig. 10  Ġ, , 
! pH !ĹŋĀj * Asp(1) ,# Asp(0) !Źñz$!ĢÀ
" D-Phe(1) ,.*¦
, Asp !¶| ,ª}t	,.Ŝ ¾ſ































Fig. 10. Radioactivity profiles of cellulose acetate electrophoresis of D-Phe(1) (closed 
circle), Asp(1) (open circle), and Asp(0) (open square) at pH 5.0 (A), pH 6.0 (B), pH 
7.0 (C), and pH 7.4 (D). 
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ĩ 4 Ĭ 111In ôŚVTHL! in vitro Ŕw 
 
ĩ  1 ƅ  111In ôŚVTHL!]C<`ETGc6IE8  (RRA)  ,/ 
SSTR ŏÊ!Ŕw 
 
 Í 111In ôŚVTHL! SSTR $!ě×ęŏÊ3Ą®/), 
FXKDGHb-14 ! 11 ĕĚ! Phe 	 Tyr $ĺÙ0, ! Tyr 	 125I 
ôŚ0 [125I]Tyr11-FXKDGHb-14 (Fig. 11) Ń²tĔ3Ē/ 
RRA 3ŒĔ. Ń²tĔ!ŘŎ " SSTR2 3Ƌ³À ĘĎ/]I
KńŅ	4ēì AR42J ĳĽ3ŬÐ.54,55) 
 
 
Fig.11. Chemical structure of [125I]Tyr11-somatostatin-14. 
 
 ¡ƈ AR42J ĳĽ-ŘŎd®Ű!Ń²tĔ d®Ű! [125I]Tyr11-
FXKDGHb-14 , ŤŘŎƂÝµÊ 115In 	Ůr 115In-D-Phe(1), 
115In-Asp(1) ,# 115In-Asp(0) 3Ĥ!ćÀā 30 °C  25 Ŷ 8
b>[UcK. !Ķî, 115In-D-Phe(1)  115In-Asp(0) ! IC50 y"0
0 4.0 nM, 3.2 nM ī0, SSTR $!ŏÊ ¦
»"Ŗ)-0
. dá, 115In-Asp(1) ! IC50y" 100 nM ofØ®0, SSTR  ´/
ŏÊ!ñÀ!sg	Ŗ)-0, Asp(1) !łė$!żĥ"çÄ
 
(Fig. 12). Octreotide ŗ¶t! SSTR !Ķ3ÑS5cXAS;6òŧ",  
-Phe-D-Trp-Lys-Thr- ! 4 !6YOůø¢	/	Ğ-0/.56,57) S
5cXAS;6òŧ-ū N éĨ D-Phe 3 Asp  ĺÙ Asp(1) ! 
²tŏÊ"ĸÓ0/	çÄ0	, ¯Ż "²tŏÊ"










D-Phe " SSTR !ƋŏÊ!ĸÓ ÈƆ!òŧ	., VTHLų N é





Fig. 12. Displacement of [125I]Tyr11-somatostatin-14 by 115In-D-Phe(1) (closed circle 
with dotted line), 115In-Asp(1) (open circle) or 115In-Asp(0) (open square) in AR42J 
tumor cell membranes. Values are expressed as % of maximal bound ± SE (n = 3). 
 
 
ĩ 2 ƅ ¡ƈłėĳĽ$! 111In ôŚVTHL!š( 
 
 ¡ƈ AR42J ĳĽ3Ē D-Phe(1), Asp(1) ,# Asp(0) ! in vitro łė
żĥÊ3Ŕw.58) 
 111In ôŚVTHL3 37 °C, 5% CO2 ëpg ¡ƈ AR42J ĳĽ8b>[
UcK, 0.5, 1, 2 ,# 4 ãŶÅ!ĳĽ3, ĳĽ!Ýµľ,#Gb
P?ŞŰ3Ą®. !Ķî, Asp(0) !łėĳĽ$!š(" D-Phe(1) 
ó ĵãę ¤! ´, Asp(1) łėĳĽ$!š("ƇŇ sg
 (Fig. 13). Asp(1) !ƇŇĳĽš(!sg", ƅĠ SSTR $!ŏ
Ê!sg ēì/Ļ-0.  
 
















Fig. 13. Comparison of the cell-uptake of Asp(1) (open circle) and Asp(0) (open square) 
with D-Phe(1) (closed circle) in AR42J tumor cells. Values represent %dose/mg protein. 
 
 
ĩ 3 ƅ š(ŷ±¯Ɗ 
 
 ƅĠ Asp(0) !¡ƈĳĽ$!š(	, ôę/ SSTR !Č
ĖęĶ ¢/!3Ř%/), ƂÝµÊ! octreotide 3ã ā
£! Asp(0) ! AR42J ĳĽ$!.š(3Ŕw. Asp(0) Ĥ
!ćÀ! octreotide 3ã ā, 37 °C, 5% CO2 ëpg 4 ãŶ8b>[
UcKÅ, ĳĽ!Ýµľ,#GbP?ŞŰ3Ą®. !Ķî Fig. 14  
Ġ, , ā octreotide !ćÀ v« Asp(0) !š(	Ă·
-, Asp(0) !łėĳĽ$!żĥ", 	4ĳĽŌƃ ĘĎ/ SSTR 




Fig. 14. Asp(0) uptake by AR42J tumor cells in the presence of varying concentrations 
of octreotide. Significant differences from control (without inhibitor) were identified 
using Dunnett’s test (*p < 0.05). 
 
 
ĩ 5 Ĭ 111In-DTPA-Asp0-D-Phe1-octretoide ! in vivo Ŕw 
 
ĩ 1 ƅ 111In-DTPA-Asp0-D-Phe1-octretoide ! in vitro ŉĆj­®Ê!Ŕw 
 
 ¡ƈĳĽ3Ē in vitro ¯Ɗ!Ķî, Asp(0) 	 SSTR ĘĎłėĳĽ$Č
Ėę żĥ/	Ġ0!, in vivo !ðœ ĢŊ. In vivo ¯Ɗ
 {Ħ, Asp(0) !ŉĆj!­®Ê3 in vitro Ŕw. 
 Asp(0) 3 ddY X9D,.ŘŎàƌŉĆj 1 ,# 3 ãŶ8b>
[UcKÅ, E_acD6EJcKŃſúþý, TLC ,# HPLC 
í, è¥t!Ýµ¬ęİÀ3ī. !Ķî8b>[UcK 3 
ãŶÅ * Asp(0) !Ýµ¬İÀ" 95% of	Ŗ)-0, Asp(0) "
X9DŉĆjd®ãŶ"Ő0/­® « /	Ġ0
 (Fig. 15).  
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Fig. 15. Percent radioactivity of intact Asp(0) after incubation in murine plasma. 
 
 
ĩ 2 ƅ ddY X9D!t~½ 
 
 Ĭ!ðœ ,. Asp(0) !ŉĆj!­®Ê	Ñx0-, ddY 
X9D ÏhÅ!t~ÝµľÔ3 D-Phe(1) ùŠ. 
 D-Phe(1) '" Asp(0) 3 ddY X9D ¸Ɓŀ,.ÏhÅ!t~Ýµ
ľ½3 Table 1 ,# 2  Ġ. 0!VTHL*ŉĀj-Ŧ+ 
ÿ§, ðœ}!ãŶĈ ŁŅä*ƋÝµľżĥ	Ŗ)-0
. ', ÏhÝµľ"k ¹j$Öü0.  
 Asp(0) !Łżĥ", Ïh 30 - 6 ãŶÅ D-Phe(1) !Łżĥù%
åË sy3Ġ (p < 0.05). !Ķî" Asp !VTHLų$!qŴn 
,/Ŝſņ!nh	, Łżĥ!sĂ åĒ	/3Ü)Ġ*!	/. 
, Ïh 24 ãŶÅ", Asp(0) !Łżĥ"sy3Ġ"/*!!, 





Table 1. Biodistribution of radioactivity after intravenous administration of D-Phe(1) in normal ddY mice. a 
 Time after administration 
Organs 10 min 30 min 1 h 3 h 6 h 24 h 
Blood 4.24 ± 0.48 1.16 ± 0.14 0.33 ± 0.11 0.01 ± 0.01 0.01 ± 0.01 0.00 ± 0.00 
Plasma 8.12 ± 0.91 2.25 ± 0.44 0.61 ± 0.23 0.05 ± 0.03 0.03 ± 0.02 0.01 ± 0.02 
Liver 1.47 ± 0.12 0.53 ± 0.05 0.28 ± 0.09 0.18 ± 0.01 0.43 ± 0.65 0.07 ± 0.01 
Kidney 29.89 ± 7.55 36.77 ± 7.04 31.97 ± 9.27 23.93 ± 4.25 14.52 ± 1.70 2.95 ± 0.68 
S. intestine 1.50 ± 0.13 0.78 ± 0.11 0.81 ± 0.15 0.77 ± 1.00 0.19 ± 0.06 0.14 ± 0.08 
L. intestine 1.14 ± 0.15 0.51 ± 0.09 0.34 ± 0.09 1.74 ± 0.71 1.17 ± 0.34 0.71 ± 0.38 
Stomach 1.76 ± 0.39 1.01 ± 0.35 0.76 ± 0.29 0.76 ± 0.54 0.46 ± 0.18 0.35 ± 0.13 
Spleen 1.63 ± 0.21 0.58 ± 0.05 0.33 ± 0.14 0.23 ± 0.05 0.14 ± 0.06 0.07 ± 0.06 
Pancreas 3.53 ± 0.36 1.86 ± 0.44 1.20 ± 0.29 0.66 ± 0.12 0.57 ± 0.07 0.21 ± 0.04 
Lung 5.69 ± 0.82 2.66 ± 0.23 1.54 ± 0.45 0.93 ± 0.26 0.73 ± 0.19 0.35 ± 0.07 
Heart 1.64 ± 0.31 0.54 ± 0.11 0.14 ± 0.06 0.02 ± 0.02 0.02 ± 0.03 0.02 ± 0.03 
Muscle 1.05 ± 0.12 0.24 ± 0.15 0.06 ± 0.02 0.00 ± 0.01 0.01 ± 0.02 0.01 ± 0.03 
Urine b  –   –   –   –   –  78.87 ± 7.38 
Feces b  –   –   –   –   –  7.63 ± 6.98 
a Expressed as a percentage of injected dose per gram. Mean ± SD of five animals for each point. 
b Expressed as a percentage of injected dose. 
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Table 2. Biodistribution of radioactivity after intravenous administration of Asp(0) in normal ddY mice. a 
 Time after administration 
Organs 10 min 30 min 1 h 3 h 6 h 24 h 
Blood 3.86 ± 0.33 1.43 ± 0.19 0.32 ± 0.07 0.03 ± 0.02 0.02 ± 0.01 0.01 ± 0.01 
Plasma 6.99 ± 0.49 2.81 ± 0.37 0.58 ± 0.08 0.05 ± 0.04 0.04 ± 0.04 0.01 ± 0.01 
Liver 1.09 ± 0.14 0.60 ± 0.14 0.24 ± 0.04 0.13 ± 0.02 0.11 ± 0.01 0.08 ± 0.01 
Kidney 21.19 ± 5.82 18.01 ± 7.14 c 12.81 ± 2.41 c 10.24 ± 0.83 c 9.80 ± 2.90 c 4.63 ± 1.44 c 
S. intestine 0.99 ± 0.07 0.65 ± 0.08 0.42 ± 0.02 0.23 ± 0.05 0.11 ± 0.02 0.19 ± 0.14 
L. intestine 0.92 ± 0.05 0.60 ± 0.09 0.30 ± 0.05 0.74 ± 0.06 0.58 ± 0.24 0.61 ± 0.53 
Stomach 1.40 ± 0.29 2.02 ± 0.46 1.02 ± 0.17 0.46 ± 0.09 0.29 ± 0.11 0.33 ± 0.17 
Spleen 1.10 ± 0.09 0.64 ± 0.09 0.36 ± 0.05 0.20 ± 0.04 0.17 ± 0.05 0.15 ± 0.05 
Pancreas 2.70 ± 0.18 1.60 ± 0.17 0.71 ± 0.08 0.37 ± 0.07 0.40 ± 0.14 0.34 ± 0.08 
Lung 4.46 ± 0.49 2.72 ± 0.67 1.34 ± 0.32 0.61 ± 0.14 0.71 ± 0.18 0.35 ± 0.09 
Heart 1.39 ± 0.12 0.59 ± 0.09 0.14 ± 0.06 0.02 ± 0.02 0.02 ± 0.02 0.04 ± 0.05 
Muscle 0.87 ± 0.12 0.35 ± 0.06 0.13 ± 0.08 0.02 ± 0.04 0.02 ± 0.04 0.00 ± 0.00 
Urine b  –   –   –   –   –  74.09 ± 11.49 
Feces b  –   –   –   –   –  7.33 ± 8.53 
a Expressed as a percentage of injected dose per gram. Mean ± SD of five animals for each point. 
b Expressed as a percentage of injected dose. 
c p < 0.05. 
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 111In-DTPA  WrJ#IQa:957, /@70-6A13
£OU'³ )k, ?44A=²µ)G¯*V	, }wemG¯
 N ,<8¼ 1 \ W 111In-DTPA->8,<8¼*p
(.59) pwemG¯£_uPVStx%("¢
&)', G¯m£¨·»d½¬)	(.60) z 
D-Phe(1) & 111In-DTPA-D-Phe-OH }wemG¯p(

]Z)',61,62) 
)&]Zl Asp(0) }G¯ 
111In-DTPA-Asp-OH *p(
vb)(. DG¯&"m
Å	TW(, ,<8¼M¿¹& 111In-DTPA-Asp-OH 




























more lipophilic side chain more hydrophilic side chain
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Fig. 17. Proposal mechanism of excretion of 111In-DTPA-D-Phe-OH and 111In-DTPA-





















 3 Ä s+;.3JOQi 
 
 ddY ;.3	, qC{	(" Asp(0) %(¦Â
I*®!,  in vivo §«m*s+;.3 63,64) *	­K
 D-Phe(1) JOQi*±. 
 D-Phe(1)   Asp(0) * AR42J £;.3gÃ¥%'qC, 
)) 1, 3 % 24 |Ák	(we¤¡Qi*­K. )
) * Table 3 . 
  2 Ä´ ddY ;.3JOQiX, &:957"ª
E&¸#`, ¦©H_j©[	(we¤Â~oh
®!&). ddY ;.3^WX, Asp(0) ¦Â¾, q
C 1 |Ák D-Phe(1) ¦Â¾ 56% f 3 |Ák ~o
IL*, 24 |Ák¶° D-Phe(1) %'"~oÅ	L*. 
 Asp(0) §Â¾, qC 1 % 3 |Ák D-Phe(1) X
', qC 24 |Ák¦ÂX Asp(0) y~oÅL* 
(p < 0.05). Asp(0)  D-Phe(1) X§£	" SSTR  W
k/@70-6A13%'£OU'³ ), ?44A=«(
¢&)(.65,66) ?44A=G¯*V	 Asp(0) &wemG¯






Table 3. Biodistribution of radioactivity after intravenous administration of D-Phe(1) and Asp(0) in AR42J tumor-bearing nude mice. a 
 Time after administration 
D-Phe(1) Asp(0) 
Organs 1 h 3 h 24 h 1 h 3 h 24 h 
Blood 0.16 ± 0.03 0.02 ± 0.00 0.00 ± 0.00 0.17 ± 0.05 0.06 ± 0.03 0.00 ± 0.00 
Plasma 0.34 ± 0.03 0.04 ± 0.04 0.00 ± 0.00 0.52 ± 0.16 0.07 ± 0.05 0.04 ± 0.05 
Liver 0.24 ± 0.04 0.12 ± 0.02 0.05 ± 0.01 0.16 ± 0.03 0.10 ± 0.01 0.06 ± 0.01 
Kidney 34.10 ± 2.34 26.05 ± 2.85 2.93 ± 0.81 19.15 ± 1.60 c 16.99 ± 2.43 c 4.98 ± 0.37 c 
S. intestine 0.69 ± 0.03 0.20 ± 0.10 0.24 ± 0.15 0.29 ± 0.04 0.17 ± 0.06 0.27 ± 0.26 
L. intestine 0.19 ± 0.13 0.79 ± 0.05 0.87 ± 0.31 0.21 ± 0.02 0.46 ± 0.09 1.26 ± 1.04 
Stomach 0.64 ± 0.31 0.36 ± 0.08 0.25 ± 0.11 0.52 ± 0.26 0.55 ± 0.41 0.32 ± 0.12 
Spleen 0.25 ± 0.06 0.12 ± 0.03 0.07 ± 0.01 0.18 ± 0.05 0.13 ± 0.04 0.12 ± 0.03 
Pancreas 0.64 ± 0.08 0.29 ± 0.04 0.11 ± 0.01 0.52 ± 0.10 0.36 ± 0.03 0.20 ± 0.04 
Lung 1.16 ± 0.08 0.67 ± 0.09 0.35 ± 0.11 1.42 ± 0.19 0.70 ± 0.11 0.32 ± 0.07 
Heart 0.11 ± 0.05 0.02 ± 0.02 0.00 ± 0.01 0.09 ± 0.05 0.02 ± 0.02 0.00 ± 0.01 
Muscle 0.06 ± 0.05 0.05 ± 0.02 0.00 ± 0.01 0.10 ± 0.13 0.03 ± 0.03 0.00 ± 0.00 
Tumor 5.68 ± 0.60 3.91 ± 1.00 1.78 ± 0.37 4.87 ± 0.51 4.27 ± 0.43 2.30 ± 0.21 c 
Urineb  –   –  65.32 ± 19.25  –   –  54.10 ± 27.23 
Fecesb  –   –  18.31 ± 14.64  –   –  27.80 ± 23.26 
a Expressed as a percentage of injected dose per gram. Mean ± SD of three to four animals for each point. 
b Expressed as a percentage of injected dose. 
c p < 0.05. 
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 6 ¡  1 §x 
 
   NET ·²¯gn&	%  111In-DTPA-D-Phe1- 
octreotide (D-Phe(1)) Ð­Î='z, Asp ½Ï°':
8¹d>  111In-DTPA-Asp1-octreotide (Asp(1)) "  111In-DTPA-Asp0-D-
Phe1-octretoide (Asp(0)) 'Qt, &#o¾' in vitro " in vivo ¸
@.  
N )3/Ç'¨| Asp(1)  in vitro 	%®Îo" 
SSTR ´UoÒ±=7b, N  D-Phe 'ÆF9A^ 
Asp '<Ê:K Asp(0)  D-Phe(1) R®Îo'¦y. 


# octreotide  N  D-Phe Oa>´Uo"®Îo
¦yÈ³hJ'	%©#&. 
ddY 2*+"w(2*+>CEf_Ó¥, v8j	
%  Asp(0)  D-Phe(1) Á­~c¬Î'r=







Asp(0)  Asp dB"%½Ï°:8", iÃ$­e£ £«








¨ 2 ¦ 111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide \y ddY :.0
KRWxÀL 
 
¨ 1 ª 111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide ¿¾ 
 







Ó¤+~^	'´.  111In-DTPA-D-Phe1-octreotide (D-Phe(1)) 
], jwGÃ 111In-DTPA-D-Phe-OH +C's('
9726, * Asp(0)  N §9726Î D-Phe +IÏFV
  111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide (D-Phe(−1)) +¿¾ 
(Fig. 18).  
 
 













¨ 2 ª 111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide \yÔwÆÀ
L 
 
¨ 1 × 111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide \y 
  
 D-Phe(−1) , ¨ 1 ¦ ¨ 2 ª] H-Thr(t-Bu)-ol-2-		

, ÄUÙK DTPA-D-Phe−1-Asp0-D-Phe1-octreotide + Fmoc 
` \y$&[ 27% u. ±	UÙK9726+/35X, 111In 
Ä. u%(jw9726+1=>@0,14@5¹ÔW$
 TLC F, ' D-Phe(−1) + 95% HBjXe¬pu. 
°%, D-Phe(−1)  N §IÏ 2  D-Phe # DTPA  
111In ÍKqyZvrÖ+C	¢(. 
 
¨ 2 × 111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide ÔwÆÀL 
 
 ¨ 1 ¦ ¨ 3 ª], D-Phe(−1) ÔwÆ+«K)Êtm
$» pH iv' pH 5.0, 6.0, 7.0 $ 7.4 <?Ì²¼D, 1
=>@0,14@5¹ÔW$&ÀL. °, Fig. 19 ¢$
	( pH ²¼D	# D-Phe(−1)  D-Phe(1) $&#Ò
N£Wpb	
, ScQK$&ÅoÔ	'¢(. !
, 9726Î N §IÏFV 2  D-Phe  Asp kP
K9726FC(ÅÔºrÖ+C	#¡Á(. %, 
D-Phe(−1) Y%ÒN£Wp, Q pH 	OÉ  
Asp(0) ©











Fig. 19. Radioactivity profiles of cellulose acetate electrophoresis of D-Phe(1) (closed 
circle), Asp(0) (open circle), and D-Phe(−1) (closed square) at pH 5.0 (A), pH 6.0 (B), pH 7.0 
(C), and pH 7.4 (D). 
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¨ 3 ª 111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide  ddY:.0'K
RWxÀL 
 
¨ 1 × 111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide »DfgwÀL 
 
 D-Phe(−1)  in vivo hÚO¥, ¨ 1 ¦ ¨ 5 ª ¨ 1 ×]»
Dfgw+ in vitro ÀL. D-Phe(−1) :.0Ü»D 3 
Ð-?/;8@5t	#, jXe¬p 95% HBÁ"%(, 
:.0»DAgÐS½('
, fgda'¢(
 (Fig. 20). 
 
 
Fig. 20. Percent radioactivity of intact D-Phe(−1) after incubation in murine plasma. 
 
 
¨ 2 × 111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide  ddY :.0KR
Sn 
 
 D-Phe(−1) »Dfgw{M(, ¨ 1 ¦ ¨ 5 ª ¨ 2 
×] D-Phe(−1) ! D-Phe(1) + ddY :.0lÕ·$&zC, 




Table 4. Biodistribution of radioactivity after intravenous administration of D-Phe(1) and D-Phe(−1) in ddY mice. a 
 Time after administration 
D-Phe(1) D-Phe(−1) 
Organs 1 h 3 h 24 h 1 h 3 h 24 h 
Blood 0.37 ± 0.02 0.02 ± 0.00 0.01 ± 0.02 0.47 ± 0.17 0.05 ± 0.01 0.00 ± 0.00 
Plasma 0.55 ± 0.13 0.00 ± 0.00 0.04 ± 0.07 0.75 ± 0.38 0.05 ± 0.07 0.04 ± 0.07 
Liver 0.29 ± 0.04 0.13 ± 0.02 0.06 ± 0.01 0.38 ± 0.15 0.20 ± 0.01 0.06 ± 0.01 
Kidney 26.28 ± 8.36 14.99 ± 3.46 1.60 ± 0.14 13.49 ± 5.37 9.11 ± 1.05c 0.71 ± 0.17c 
S. intestine 1.25 ± 0.93 0.43 ± 0.23 0.10 ± 0.01 1.38 ± 0.18 1.36 ± 0.16 0.34 ± 0.04 
L. intestine 0.35 ± 0.07 1.04 ± 0.22 0.54 ± 0.16 1.15 ± 0.29 2.08 ± 0.52 1.22 ± 0.67 
Stomach 4.09 ± 4.58 1.14 ± 0.49 0.39 ± 0.20 4.50 ± 0.08 4.50 ± 1.60 c 0.84 ± 0.11 
Spleen 0.24 ± 0.04 0.19 ± 0.03 0.12 ± 0.07 0.67 ± 0.09 c 0.42 ± 0.07 c 0.21 ± 0.09 
Pancreas 0.57 ± 0.11 0.33 ± 0.06 0.12 ± 0.03 5.92  ± 1.10 c 2.98 ± 0.45 c 1.27 ± 0.26 c 
Lung 1.60 ± 0.18 0.92 ± 0.11 0.43 ± 0.05 6.66 ± 1.38 c 3.80 ± 1.07 c 1.63 ± 0.27 c 
Heart 0.15 ± 0.05 0.03 ± 0.02 0.05 ± 0.06 0.33 ± 0.19 0.05 ± 0.02 0.04 ± 0.06 
Muscle 0.10 ± 0.03 0.01 ± 0.02 0.03 ± 0.03 0.11 ± 0.00 0.02 ± 0.02 0.05 ± 0.06 
Urineb  –   –  76.79 ± 6.05  –   –  62.99 ± 19.31 
Fecesb  –   –  3.44 ± 1.37  –   –  12.0 ± 9.06 
a Expressed as a percentage injected dose per gram. Mean ± SD of three to four animals for each point. 
b Expressed as a percentage of injected dose. 




&. Aµ«# D-Phe(−1) 6 3 n²_VWTP&
¦'	&, ?©NrRE<@\$
'&. D-Phe(−1) A« Asp(0) Hx, o!·	kZ´
¦ $', f5kZ7[6gz'. D-Phe(−1) ´
¯f5 1 n²_ D-Phe(1) ´¯ 51.4%, 3 n²_ 60.7%, 24 n
²_ 44.3% (. #§¶	f5 24 n²_´
 , l£¡  D-Phe(−1)   D-Phe(1) yªpc;	  (p < 
0.05), v¢?n²´;}(¦ , f5±n²®_´
(jM&eC. u9¨EUw­(d, /-+
,° N s D-Phe ($:±B£¡
&kZ~
jMpD(L	&. 
 3m, 	 f5 3 n²_ 24 n²_, 	
v¢?n² D-Phe(−1) kZ´ D-Phe(1) (4O%pc
·. '# SSTR QJ'
	&.67,68) 	 SSTR ³&hQJ	!
 mRNA 2.1·	",69) D-Phe(1) f5_0)*	·	´
(¦ =QJ'	&.70) ` ddY 0)*
&
·	´, $	·´! D-Phe(−1)  SSTR 
G#&´&iW'&. 
 ddY 0)*(	tv¢	 , D-Phe(1) y  D-Phe(−1)  
SSTR Npc·	kZ´¦ $'$, D-Phe(−1) 
 SSTR Y& Ka D-Phe(1) #%!·	Fa$'. 
 , SSTR (·X]& NET Y D-Phe(−1) ·	kZ´
8b', D-Phe(1) yª´aI4q^'. , D-Phe(1) 
# D-Phe(−1)  SSTR Y& Ka¤>	 3   2 
¥«&. 
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ù 4 û 111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide ­T¥ ddY G3:
,Č·ĊmÆ 
 
ù 1 ł ·©\ğßË 111In-DTPA-D-Phe-OH, 111In-DTPA-Asp-OH )
! 111In-DTPA-D-Phe-Asp-OHw¬ 
 
 D-Phe(−1) 0 ddY G3:"­T¥ 24 ¿ĺ,ČĿõ_ÚÍÉ, 
^\ğßá¬),0ðĜ,&, D-Phe(1), Asp(0) $ D-
Phe(−1) 0 ddY G3:­T, 24 ¿ĺ¥ČĎkÐ,·©wß
w£0 HPLC mÆðĜ,. $, ÏG3:" D-
Phe(−1) ­Të¥* 6 ¿ĺ¥$, 6 * 24 ¿ĺ¥$³l-
0|, V·Ċ' HPLC mÆ. 
 ņiö, ·©\ğßá¬XÜ-, 111In-DTPA-D-Phe-OH 
)! 111In-DTPA-Asp-OH ¬0ęä. $, D-Phe(−1) EC<?ĸ 
N Ãøf D-1HAĵ0ą+ĩÀ, -D-Phe-Asp-D-Phe- ĳo0À
+, Þ L-1HAĵ*,EC<?ĳoÑ#\ğmĘ¯®0ñ
XÜ-,. &, ČĎk 111In-DTPA 9EC<?Ā
  111In-DTPA-D-Phe-Asp-OH ÐĆ*-& , 111In-DTPA-D-Phe-OH 
)! 111In-DTPA-Asp-OH t 111In-DTPA-D-Phe-Asp-OH 'Ë
¬,. 
 --·©\ğßËËĠrŅ`¬ÿĤ0 Scheme 3, 4 )! 
5 ñ. DTPA-D-Phe-OH )! DTPA-Asp-OH , mDTPA fĸdġ1H
Aĵ0Øì{¨)Ą¥ , dġĽzüē0ÿ-- 
56% )! 69% |à¬. DTPA-D-Phe-Asp-OH  Ģ Fmoc-
Asp(Ot-Bu)-Alko-PEG Ìċ0lèy¹ Fmoc 0Ľz¥, Fmoc-D-Phe-OH, 
mDTPA 0ŃÎĄ, ĵ),dġĽzÌċ*n+l, ā
ī





















































































Scheme 5. Synthesis of DTPA-D-Phe-Asp-OH. 
 
 Î, ¦*-ËĠrŅ`0 pH 5.5 ĴĵăĒØV 111InCl3 Û 1 ¿
ĺ2O5LDP>,ËĠ, êé,·©Ë0 95% ]R·
wéý ¦. ·©ËqĭĞēŁ·© 115In-DTPA-
D-Phe-OH, 115In-DTPA-Asp-OH )!  115In-DTPA-D-Phe-Asp-OH   HPLC 




ù 2 ł 111In-DTPA-octreotide ĝ`0 ddY G3:"­T¥ČĎ)!
V·Ċ HPLC mÆ 
 
 D-Phe(1), Asp(0) $ D-Phe(−1) 0 ddY G3:­T¥ČĎ,
·©\ğß0mÆ,&, EC<?­T 24 ¿ĺ¥ôCN=1P
;ļs0%ăĒØ§)+Ý×¥ČĎ0¶l, FK9@P>
0Ğē.62) ČFK9@P>ı§)+RÙ0mŀ, ·ĊRÙ"
°luà0Ó&., -- 78%, 91% )! 93% 	+, ČĎÐ
,·ĊĲm°l-. 
 ¦*-RÙ·Ċw£0Ô,&, īì HPLC mÆ0¼
































0ñ. Fig. 21 (A), (B) )! Fig. 22  (B) Ĝ&*-,ėwß D-
Phe(1), Asp(0) *!Ë 111In-DTPA-D-Phe-OH )! 111In-DTPA-D-Phe-
Asp-OH 6NG>7MIĜ&*-, 2 ÄBP6, 111In  DTPA ķ
`0£¬,ľá¬,ķå©`ãÅ,'	+, ìYµ,
½-,. 62,71–73) 
 jEC<?­T 24 ¿ĺ¥RÙ, d²¿ĺ 50 m[Ĩėw
ßBP6Ĝ&*-, )+ïd²¿ĺĔ¸BP6Ĝ&*-. 
¬·©Ë¿mÆĀÇ, D-Phe(1) )! Asp(0) *-
- 111In-DTPA  N Ãø1HAĵ 1 ÐĀ 111In-DTPA-D-Phe-
OH )! 111In-DTPA-Asp-OH á¬Ĝ&*- (Fig. 21(C)).  
 Q», D-Phe(−1) RÙ*, 2 ôń·©\ğßá¬Ĝ&*-, ¢
pXÜĮ+ 111In-DTPA-D-Phe-OH 0á¬,', XÜ\ğ¯®©
),Ć*-, 111In-DTPA-D-Phe-Asp-OH á¬'ðĜ- (Fig. 22C). 
 Fig. 21 )! Fig. 22 ñË HPLC 6NG>7MI0ÑĦ,, 
111In-DTPA-D-Phe-OH )! 111In-DTPA-D-Phe-Asp-OH d²¿ĺ, -
' 111In-DTPA-Asp-OH )+'Ĺ. īì HPLC ìæÒ© 
ODS, òvìÒ0âUìwßmĳ*4MIk0òv,&, 
īì HPLC d²¿ĺmĳc¸¡ìĻ,.74) /, 
111In-DTPA-Asp-OH )+Ĺd²¿ĺ0ñ  111In-DTPA-D-Phe-OH )! 
111In-DTPA-D-Phe-Asp-OH , æÒ© ODS )+¡
mĳ-




Fig. 21. RP-HPLC radioactivity profiles of standard 111In-DTPA-conjugated compound 
(A) and (B). Co-injection of the kidney homogenate with the standard compounds (C). 
 
   
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Fig. 22. RP-HPLC radioactivity profiles of standard 111In-DTPA-conjugated compound 
(A) and (B). Co-injection of the kidney homogenate with the standard compounds (C). 
 
 , D-Phe(−1) ­T¥ČĎá¬ 111In-DTPA-D-Phe-Asp-OH 
9EC<?þĉ"³Ö-,, 111In-DTPA-D-Phe-OH \ğ-
*³Ö-,S¾	,.  D-Phe(−1) ­T¥|




Fig. 23. RP-HPLC radioactivity of urine by 6 h (A) and 6–24 h (B) postinjection of D-
Phe(−1); the open and closed inversed triangle show 111In-DTPA-D-Phe-Asp-OH and 
111In-DTPA-D-Phe-OH, respectively. 
 
 D-Phe(−1) ­Të¥* 6 ¿ĺ¥$|V·Ċ, W
Âw` D-Phe(−1) 	+, D-Phe(1) (Z·©EC<?ÊĲ
mÂw`V³Ö-,¾* (Fig. 23(A)). ­
 41 
T¥  6 ¿ĺ*  24 ¿ĺ¥'Wĕ·ĊÂw`  D-
Phe(−1) ãÅ, d²¿ĺ 5–15 mĺ/	,' 111In-
DTPA-D-Phe-OH )! 111In-DTPA-D-Phe-Asp-OH ãÅ,BP60Ĝ&. 
, 111In-DTPA-D-Phe-Asp-OH  111In-DTPA-D-Phe-OH \ğ-
*³Ö-,
, -ďĥV"ë´³Ö-,0ñ
, . VĜ&*- 111In-DTPA-D-Phe-Asp-OH )!  111In-DTPA-D-Phe-
OH , ČĎ]Ď (a \ğĊŇĈĎ) m D-Phe(−1) 
mĘ-, ·©\ğßČĎ"òđ¥³Ö-~Ċ©'Ć*-
,. , ĈĎ" D-Phe(−1) ĿõĶ­T 1 )! 3 ¿ĺ¥-
- 0.38 )! 0.20%ID/g ó _e	+, V·©\ğßČĎ
Ŀõ·©EC<?ãÅ,Ć,¢	,. /, 111In-
DTPA-D-Phe-Asp-OH Čþúþĉ0Ĭİ	,hmþĉčĬİ©0À
+, ā"į(³Ö-,* D-Phe(−1) ­TĹ¿ĺÿ
İ¥ČĿõ_ÚT,Ć*-.  
 $, d²¿ĺ 30 m[ĨĜ&*-ºBP6,  D-Phe(−1) \ğ
-áVó Ĺ·©EC<?	,Xª-,. , ČF
K9@P>RÙV·ĊmÆV·ĊmÆ, Qwß	




ù 5 û ù 2 ÷Ă± 
 
 Ä÷ù 1 ÷îĖ	, Čþúþĉ}+ħ$-¥á¬
,Ć*-,\ğßæÒ©íê, º·© octreotide ĝ`0Ě
ę. /, D-Phe(1) æÒ©\ğß 111In-DTPA-D-Phe-OH 0á
¬,Ć*-, 111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide (D-Phe(−1)) 0
¬, Äé©ģ0ěb. 
 D-Phe(−1) ČĿõ ddY G3:, Á¤Į+­TĹ¿ĺÿİ¥
' D-Phe(1) Ñ#À«_e0ñ. D-Phe(−1) ­T 24 ¿ĺ¥Č
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Ď* , 111In-DTPA-D-Phe-OH á¬
  111In-DTPA-D-Phe-Asp-OH 
á¬ðĜ-. UćæÒ© HPLC 6NG>7MId²¿ĺ*, 
Asp(0) *á¬, 111In-DTPA-Asp-OH )+'Ňñ-. $, 
111In-DTPA-D-Phe-OH  111In-DTPA-D-Phe-Asp-OH V³ÖĜ&*-, U
\ğßČþúþĉ*³Ö©)!³Ö©Ň D-Phe(−1) Č
Ŀõ_ÚT,Ć*-.  
 -**, Ä÷ºĚę·¬ D-Phe(−1) , ù 1 ÷Ī
# 111In-DTPA-Asp0-D-Phe1-octreotide (Asp(0)) )+'2JP9O7)!Èx
Õç"¨â~Ċg-©ģ0À,~Ċ©ñ-.  
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j 3 i 111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide wdhK~3 
 
j 1 l In vivo ~3 
 
j 1  N&)'(18:GB 
 
 j 2 i ddY )'(18:GB, SSTR %ea"z=
	 D-Phe(−1) h #, SSTR eawdC	ODt
hVI
#. 	 D-Phe(−1)  in vivo "wdhK%~3"
, j 1 i j 5 l j3 gP\<Y2|N&)'(
 D-Phe(1)  D-Phe(−1) %Fu!M,, ## 0.5, 1, 3 
 24 SJ"ODtnq:G%[, ~3. Table 5  D-Phe(1) 
 D-Phe(−1) 18:G%g. 
 ddY )'(BpW<Y, D-Phe(−1) N&)'(	{
^- ]A, X}7S` D-Phe(−1) vh D-
Phe(1) %UL+>. D-Phe(−1) wdODth, M,J 0.5–3 S
 12–13 %ID/g, 24 SJ 7 %ID/g %"5%g, X}7
S`VI! D-Phe(1) %*>!T@ D-Phe(1)  4.4 4. 
, ##wdCvz[%k9	$ D-Phe(1) M, 24 SJ
T@, 5 0.63 C, D-Phe(−1) M, 0.5 S 0.87 
!, M,QV  D-Phe(1) [	5%g. 
  D-Phe(−1) 
wdCvz[M,JSo0	*R, 1 SJ 1.01, 3 SJ
 1.33, 24 S 4.35 !, S_"	wdh #.  
 vz/?.ZHz=	, 6 ddY )'(pW<Yy
z, r, s, Ex@x SSTR2 %cbfea"];=mz
=	 D-Phe(−1)   D-Phe(1) [UL	ODth%g. 
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Table 5. Biodistribution of radioactivity after intravenous administration of D-Phe(1) and 
D-Phe(−1) in AR42J tumor-bearing nude mice. a 
 Time after administration 
 D-Phe(1) 
Organs 0.5 h 1 h 3 h 24 h  
Blood 1.21 ± 0.23 0.16 ± 0.06 0.02 ± 0.01 0.00 ± 0.01 
Plasma 2.22 ± 0.38 0.25 ± 0.12 0.03 ± 0.03 0.01 ± 0.02 
Tumor 6.85 ± 1.80 5.98 ± 1.27 3.94 ± 1.01 1.73 ± 0.31 
Kidney 32.64 ± 6.44 31.09 ± 5.71 25.16 ± 3.06 2.85 ± 0.62 
T/K ratio b 0.21 ± 0.04 0.20 ± 0.07 0.16 ± 0.04 0.63 ± 0.20 
Liver 0.50 ± 0.12 0.24 ± 0.02 0.16 ± 0.02 0.07 ± 0.01 
S. intestine 0.82 ± 0.19 0.69 ± 0.15 0.28 ± 0.05 0.28 ± 0.09 
L. intestine 0.45 ± 0.09 0.63 ± 0.39 1.10 ± 0.29 1.60 ± 0.39 
Stomach 1.23 ± 0.70 0.93 ± 0.19 0.73 ± 0.20 0.46 ± 0.11 
Spleen 0.49 ± 0.08 0.21 ± 0.05 0.14 ± 0.03 0.08 ± 0.03 
Pancreas 1.25 ± 0.22 0.63 ± 0.18 0.39 ± 0.08 0.16 ± 0.07 
Lung 2.25 ± 0.33 1.04 ± 0.25 0.45 ± 0.06 0.28 ± 0.07 
Heart 0.44 ± 0.09 0.09 ± 0.04 0.04 ± 0.02 0.01 ± 0.02 
Muscle 0.45 ± 0.33 0.06 ± 0.02 0.01 ± 0.01 0.01 ± 0.02 
Urine c  –   –   –  49.89 ± 22.24 
Feces c  –   –   –  35.27 ± 20.77 
             
 D-Phe(−1) 
Organs 0.5 h 1 h 3 h 24 h 
Blood 1.33 ± 0.11 0.29 ± 0.04 d 0.03 ± 0.00 d 0.01 ± 0.01 
Plasma 2.29 ± 0.28 0.53 ± 0.06 d 0.03 ± 0.03 0.01 ± 0.03 
Tumor 13.61 ± 2.28 d 12.57 ± 4.36 d 13.37 ± 5.11 d 7.67 ± 1.31 d 
Kidney 15.66  ± 0.92 d 12.65 ± 1.49 d 10.53 ± 1.47 d 1.78 ± 0.21 d 
T/K ratio b 0.87 ± 0.15 1.01 ± 0.38 1.33 ± 0.64 4.35 ± 0.92 
Liver 0.54 ± 0.06 0.27 ± 0.03 0.21 ± 0.06 0.11 ± 0.01 d 
S. intestine 1.39  ± 0.08 d 1.28 ± 0.25 d 1.12 ± 0.40 d 0.48 ± 0.20 
L. intestine 1.07  ± 0.10 d 0.88 ± 0.14 2.19 ± 0.65 d 1.94 ± 0.66 
Stomach 5.68  ± 1.42 d 3.83 ± 0.54 d 2.70 ± 0.54 d 1.52 ± 0.25 d 
Spleen 0.78  ± 0.09 d 0.61 ± 0.06 d 0.32 ± 0.03 d 0.22 ± 0.04 
Pancreas 6.24  ± 0.36 d 4.39 ± 0.21 2.28 ± 0.14 d 1.04 ± 0.06 d 
Lung 4.97  ± 0.68 d 3.94 ± 0.39 d 2.92 ± 0.60 d 1.24 ± 0.24 d 
Heart 0.57  ± 0.03 d 0.16 ± 0.05 0.07 ± 0.03 0.04 ± 0.06 
Muscle 0.30 ± 0.08 0.07 ± 0.03 0.01 ± 0.01 0.05 ± 0.08 
Urine c  –   –   –  58.14 ± 19.85 
Feces c  –   –   –  23.68 ± 21.22 
a Expressed as a percentage injected dose per gram. Mean ± S.D. of three to four animals for 
each point. b Tumor to kidney ratio. c Expressed as a percentage of injected dose. d p < 0.05. 
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Ĭ 2 ƈ In vivo TbL?cBµƌ 
 
 ƈů)Ŋĝ1' SSTR ğēō¢"4 D-Phe(−1) $ƍß¹ņ
ƂĪ
, SSTR $đĜĠ!ĸ"©4$	8ĥš4.", in vivo 
TbL?cBµƌ8µä. ļWUKOŻ 0.1 µg $ D-Phe(−1)  





ħœŁ254Ói 3 èžÉ"¾Ā, ß¹ņ$ĶĿÁ
8şw. $ĸó8 Table 6 "Ħ.  
 
Table 6. Biodistribution of radioactivity at 3 h after intravenous administration of     
















a Expressed as the percentage injected dose per gram. Mean ± SD of four animals for 
each timepoint. b Co-injection with 10 µg non-rabeled octreotide. c p < 0.05. 
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ĶĿ"ğē4 SSTR 8ì4., D-Phe(−1) $ SSTR ($
ĸ
Ɓ¶5"14Ł254. eã, Œć, Ńō1'ŉō%
ƅß¹Î octreotide $èÓi"1ß¹ņƂĪ$ìÏ!«
š.25
. 5% SSTR 

















Ĭ 3 ƈ 111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide 8Ö
9Y<F(ÓiÉ
$Ŋĝ1'ŉō"4ß¹ņ$ HPLC ò 
 
 D-Phe(−1) $ŊĝƂĪ
 D-Phe(1) "ā)«¯, ŽèžÙĺ¤8
ç2	"48ġĠ D-Phe(−1) ÓiÉ$Ŋĝ"ÿ±4ß¹ņ$
²Æ8ŲĢ HPLC ò´. ,ŉō"4ß¹ÎqŦĐ$
ò/µä , Ŋĝ$ĸóāū . Ö
9Y<F( D-Phe(1) ,%  D-
Phe(−1) 8Ói, 3 èžÉ1' 24 èžÉ", ī Ĭ 4 İ Ĭ 2 ƈ
ù$ãĄŊĝ1'ŉō8Þ, 55$X\EQdN	2fĉ8ƃ
É"ŲĢ HPLC ß¹ņ8ò. 







Table 7. The extract efficiencies of radioactivity for supernatants from tumor and kidney 








 üWdE Fig. 24 "% D-Phe(1)  1' D-Phe(−1) ÓiÉ 3 èž1' 





Fig. 24. RP-HPLC profiles of (A) synthetic standards, in kidney and tumor homogenates 
at (B) 3 h post-injection and (C) 24 h post-injection. The left figures show D-Phe(1) and 









30 pŮ"š.25. ,, ëĵqŦėĐ 111In-DTPA-D-Phe-OH $ĖÒ/»
Ż!
2š.25. 24 èžÉ%ŉō1'Ŋĝ$jłß¹ÎqŦĐ 
111In-DTPA-D-Phe-OH $ĖÒ
ĥš5. 
 D-Phe(−1) 8ÓiY<F$ŉō1'ŊĝX\EQdNfĉ"/, 
D-Phe(1) ù"Ói 3 èžÉ"%î¬u$SdA%Ć°, xÙèž 
30 pŮ$kžqŦĐŁ254SdA" 15 pŮ"â!Sd
A8š.. D-Phe(−1) ÓiY<F$ŉX\EQdNfĉ"š.254xÙè
ž 15 pŮ$SdA%, ß¹ÎqŦĐú $èò	2 111In-DTPA-D-
Phe-Asp-OH 4
ĥš5, Ói 3 èžÉ"% 111In-DTPA "EWU
KO$ĸß¹ÎqŦĐ$ĖÒ
ç2	!. ,, D-Phe(−1) $Ó
i 24 èžÉ$ŉX\EQdN	2%, ddY Y<FöŜªù" 
111In-DTPA-D-Phe-OH 1' 111In-DTPA-D-Phe- Asp-OH $jqŦĐ$ĖÒ
š
.25.  
eã, D-Phe(−1) ÓiÉ 24 èž"4ŊĝX\EQdNfĉ% 111In-
DTPA-D-Phe-Asp-OH 
lĖÒĐš.25, 111In-DTPA-D-Phe-OH $ĖÒ
Ż% 111In-DTPA-D-Phe-Asp-OH ā)»!	. Fig. 24(C) $ D-Phe(−1) 
$ŉō1'ŊĝX\EQdNfĉ$AbYNB^["%, xÙèž 20 p
Ů" 111In-DTPA-D-Phe-OH "ęñ4SdA
š.254. 111In-DTPA-D-Phe-
OH $ŉō$ĖÒŻ% 10.9% 4$"¸, Ŋĝ$ĖÒŻ% 3.1% 





Ħ5. ,, xÙèž 30 pŮ"š.254kžqŦ












Ĭ 2 İ 111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide $ in vitro şw 
 
Ĭ 1 ƈ ĴŅŭ-µƌ 
 
 D-Phe(−1) $ƍŊĝƂĪ"13ŠĴ!öŜ8µä4.", ¨Ɗ 
AR42J ĴŅ8Ę D-Phe(−1) $ŊĝƂĪÎ8şw. Ĭ 1 ī Ĭ 4 İ 
Ĭ 2 ƈù" D-Phe(−1) 8 37 °C, 5% CO2 ðsg"¨Ɗ AR42J ĴŅ
;c?]VdN, 5, 10 , 0.5, 1, 2 1' 4 èžÉ$ĴŅ8£, ĴŅ$
ß¹ņ1'IcRAŨŻ8Č´. $ĸó, Fig. 25 "Ħ1" D-
Phe(−1) $¨ƊŊĝĴŅ($ŭ-% D-Phe(1) ù"ķèĠ"«, 
$ƂĪŻ%$èžď D-Phe(1) 13/ìÏ"ƍ, ë¯ D-Phe(1) $





Fig. 25. Cellular uptake of D-Phe(−1) (open square) and D-Phe(1) (closed circle) in 
AR42J tumor cells. Values represent the % dose/mg protein (mean ± SE, n = 3). The 






Ĭ  2 ƈ RRA "14  111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide $  SSTR 
ŚÎ$şw 
 
 In vivo 1' in vitro š.25 D-Phe(−1) $ƍŊĝƂĪ$¤
 
SSTR ($ŚÎ«¯"ęñ4$	8ĥš4., Ĭ 1 ī Ĭ 4 İ Ĭ 1 
ƈ$ãĄù"ųťŖƅß¹Î$ 115In-D-Phe(1), 115In-D-Phe(−1), 
1'¨ƊĴŅ	2ťŖŋ·uĚ8Ę RRA 8µä. $ĸó, 
115In-D-Phe(1)  115In-D-Phe(−1) $ IC50 z%55 1.8 nM 1' 1.4 nM 
Į5, SSTR ($ŚÎ"¯!À%š.25!	 (Fig. 26). Ê




Fig. 26. Displacement of [125I]Tyr11-somatostatin-14 by 115In-D-Phe(1) (closed circle) or 
115In-D-Phe(−1) (open square) in AR42J tumor cell membranes. Values are expressed as 








Ĭ 3 ƈ ĴŅŭ-Ɓ¶µƌ 
 
 ƈ$öŜ	2  D-Phe(−1)   D-Phe(1) $  SSTR ŚÎ"À%! , D-
Phe(−1) $ƍŊĝƂĪ%·uŚÎ$«¯"ęñ!
Ħ¡
5. ƈ$ RRA %, ¨ƊĴŅ8X\EP;GťŖŋ·uĚ
8ĘöŜ$, ĖŊĝĴŅ"4 D-Phe(−1) $Ú8Ü
4ÌŘ
4Ł, Ĭ 1 ī Ĭ 4 İ Ĭ 3 ƈù$ãĄ, in vitro $
ŭ-Ɓ¶µƌ8µä. D-Phe(1) ,% D-Phe(−1) ĩ	$ĎÄ$ƅß
¹Î octreotide 8è"¨Ɗ AR42J ĴŅ"Ĉ, 37 °C, 5% CO2 ðsg 4 
èž;c?]VdN, ß¹ņ$ĴŅ($ŭ-Ż8şw. $ĸó, Fig. 
27(A) "Ħ1"ĴŅŭ-$Ĺ¸Ż% D-Phe(−1) 
 D-Phe(1) $ 4 yĨ
Äƍ/$$, ƅß¹Î octreotide 8Ĉ!	è$ĴŅŭ-8 100% 
4Ģ¸Ż"MdI8ÝĮ4 Fig. 27(B) "Ħ1" D-Phe(1)  
D-Phe(−1) $DB\;OêĽ"¯!À
š.25!!. , D-Phe(1) 
 D-Phe(−1) "¸4ƅß¹Î octreotide $ IC50 z%, 55 10.7 nM 
 6.3 nM Į5. "Ħŭ-µƌ1' RRA $ĸó8ŁÑ
4, ïµƌË25 IC50 z$Ÿ%µƌţÀ"ęñ4/$Ł25, 
jWUKO$ĴŅŭ-Ż$À8ĕĠ"Ťç4/$%!	. 
52$ĸó% D-Phe(1) 8¯Ƌ4 D-Phe(−1) $ƍŊĝƂĪ
, 
¨Ɗðsgąk$ĖŊĝĴŅ"$-š.254ēŧ3, ƅ




Fig. 27. Cellular uptake of D-Phe(−1) (open square) and D-Phe(1) (closed circle) in the 
presence of octreotide as a competitor. The Y-axis is represented in (A) as % dose/mg 
protein, and in (B) as % of the maximal uptake (without inhibitor). Values are expressed 










Ĭ 4 ƈ 111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide $ in vitro ŊĝčěÎ$
şw 
 
 ƈ,$öŜ	2 D-Phe(−1) $ƍŊĝƂĪ$¤%, ·uŚÎr
­"ęñ4Ł25. ïī Ĭ 1 İ Ĭ 3 ƈů)Ö
9Y<F$




Î"¨ƊĴŅ8Ę in vitro şw.  
 D-Phe(1) ,% D-Phe(−1) 8¨Ɗ AR42J ĴŅ 37 °C, 5% CO2 ðsg 
4 èž;c?]VdNÉ", ĴŅ­(Û54ß¹ÎWUKO$ĴŅ
($3ŭ-8ƀý4.", 1 µM $ƅß¹Î octreotide 8ì4¨
¦(mÝÉ, ĴŅ8Ä;c?]VdN. ;c?]VdN 0, 3, 6, 12 
1' 24 èžÉ"ĴŅ8£, ÿ±4ĴŅß¹ņ1'IcRAŨŻ8
Č´.58) $ĸó, üWdE$ Fig. 28(A) "Ħ1"ĴŅ"čě4
ß¹ņ$Ĺ¸Ż%, 5,$ in vitro µƌù"öŜ$èžď 
D-Phe(−1) 
 D-Phe(1) $ĳ 4 y. 	, ;c?]VdN 0 è
ž$ĴŅß¹ņ8 100% 4Ģ¸Ż"MdI8ÝĮ4, Fig. 28(B) 










Fig. 28. Externalization of D-Phe(−1) (open square) and D-Phe(1) (closed circle) from 
AR42J tumor cells. The Y-axis is represented in (A) as the % dose/mg protein, and in 











Ĭ 5 ƈ 111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide $Ŋĝŭ-ûø"ſ
4öŜ 
 
 ,"ů) RRA 1' in vitro ĴŅčěÎ$şw	2, D-Phe(1) 
$ƍŊĝƂĪ% SSTR ĸÉ"ĴŅ(3ŭ,54 “¥ŶĨ” "Ř
¤
4$%!	Ł25. Fig. 29 "%ß¹Î octreotide Ţºu
 
SSTR (ĸÉ"ĴŅ(¥4ŶĨ$÷Ř8Ħ.  
 
Fig. 29. Internalization and externalization by receptor-mediated endocytosis.76) 
 
 ĴŅŋf$ SSTR "ĸß¹ÎWUKO%, =cOC;NdDF"1





ũ (B, C), _>cO–·uŗu8ÆÒ,,ŋf(Û54ķũ (F), 




 =cOC;NdDF8.52ĴŅŬű"% ATP ! $=Q`@d
8ÌŘ4	2, D-Phe(−1) $ĴŅŭ-"=Q`@dv±ĠŶĨ

ſi4$	8ĥš4. , D-Phe(1) ,%  D-Phe(−1) 8¨Ɗ 
AR42J ĴŅ 37 °C ,% 4 °C  5 ž;c?]VdN, ĴŅ$ß¹ņ
1'IcRAŨŻ8Č´.  
 üWdE$ Fig. 30 "Ħ1", 37 °C "4 D-Phe(−1) $ĴŅŭ-
% D-Phe(1) $ 4.6 y!3, 5,$öŜù"ìÏ"ƍz8Ħ. 
37 °C  4 °C "4ß¹ÎWUKO$ĴŅŭ-8āū4, D-Phe(−1) 
1' D-Phe(1) $jWUKO 4 °C$ĴŅŭ-
ìÏ"tg, =Q`
@dv±Ġ!ŶĨ$±¥
Ħ5. ,, 4 °C $ D-Phe(1)  D-Phe(−1) 
$ĴŅŭ-"ìÏÀ%š.25!	. ĴŅ8 4 °C ;c?]VdN
ª , *+$ĴŅą
{ý4Ł25  D-Phe(−1) 1'  D-
Phe(1) %ĴŅŋf$ SSTR (ĸÉ, ĴŅ(3ŭ,5"ĴŅŔƆ"ě
,4Ł254. !7ïöŜĸó%, RRA 0ĴŅŭ-Ɓ¶µƌ






Fig. 30. Comparison of cellular uptake of D-Phe(1) (gray bar) and D-Phe(−1) (open bar) 
in AR42J tumor cell at 37 °C and 4 °C. Values represent the %dose/mg protein (mean ± 
SE, n = 3). *p < 0.05. 
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!. SSTR %, G IcRAŨÈ§$·u3, ï·u
=cO
C;NdDF"1ĴŅ"3ŭ,54ŶĨ"%, A^F_c, J;PZ





 , Fig. 29 Ħ1", ·un¥$=cOC;NdDF"1
3ŭ,5_>cO%, í=cOHd[ (A) 	2ĴŅ­(_>cO
Ûă
54ķũ (B  C), ,%_HHd[(ħœ¥4ķũ (D) (





Ł254. =cOHd[Ź"14 D-Phe(−1) $
_HHd[($ħœ










Ĭ 3 İ Ĭ 3 ī$ļØ 
 
 ïī% 111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide (D-Phe(−1)) $uÐ8
Ö
9Y<F8Ęşw, ŊĝƂĪûø"¨ƊĴŅ8Ę in 
vitro $öŜ8. D-Phe(−1) $ŊĝƂĪ%å±$ D-Phe(1) "ā) in 












 In vitro  D-Phe(−1) 
ƍŊĝƂĪ8ĦŘ¤"öŜ6, 










9Y<F8ĘöŜ/  ddY Y<F8Ęªù"  D-
Phe(−1) $ŉƂĪ%Žèž"73 D-Phe(1) "ā)ìÏ"t
Ħ5
. 	, ddY Y<F$öŜ/š.25ĖĕĠ" SSTR 8ğē4ń, 
ňō, Ōō0Ć¢Ĳ$ō¢$ƍß¹ņƂĪ/è"š.25, ŉō"
4ƅđĜĠ!ƂĪ8tĊ/$$, o$þÂō¢($ß¹ņƂĪ8«¯
4ĸó!. 	 D-Phe(−1) %, ŊĝƂĪŻ
 4 y(«¯
	2, Ói4ß¹ņŻ8 4 $ 1 (ĊŻ/ D-Phe(1) *+ĭŊ
ĝß¹ņƂĪ
řŭ,5, Şá1'ĂĞ"ÌŘ!Ŋĝß¹ņƂĪ8ĻÙ
4Ł254. Ói4ļß¹ņ8ĊŻ4!2&, SSTR 8ğē4þ
Âō¢($ƂĪŻ%/69$ŉƂĪŻ/2"ĊŻņ4 . D-
Phe(−1) $Ói"14Ū($ŕéÇƇ"%, ĽŻşw! $ŠĴ!µ
ƌ
ÌŘ"%!4












1. 111In-DTPA-D-Phe1-octreotide (D-Phe(1))  N ~¦' Asp ¯s 111In-
DTPA-Asp1-octreotide (Asp(1)) ´Ó¤, Asp aCÆÔ¸:8&

"$´Ó¤'|j?% , µÓ¤i' d?
. 





2. D-Phe(1) 21.0Î N ~¦ D-Phe ' Asp '=Ï:J 
111In-DTPA-Asp0-D-Phe1-octreotide (Asp(0)) µÓ¤i, in vitro " 
in vivo 9± D-Phe(1) R£d$, 21.0Î N ~¦ D-Phe µ
Ó¤i_%Í»it¡&.  
 
3. Asp(0)) ´Ó¤, n8fx}	 D-Phe(1) |j?
 , n8ÏzÑªËf D-Phe(1) "$ |jØ. 
NW
 D-Phe(1) " Asp(0) #´·l%&&u`i;Å
iÌ	, ©²DieÖ'8	%°#&.  
 
4. ´·l%;Å'°kwÀ¾ 111In-DTPA-D-Phe−1-Asp0-
D-Phe1-octreotide (D-Phe(−1)) ´Ó¤, n8fx}# 24 zÑ D-
Phe(1) |j?.  D-Phe(−1) µÓ¤{[ D-
Phe(1)  4.4 B$, ¹	Z['¡. 
µÓ¤Z[, 
21.0Î N ~¦ −1 >aC 2  D-Phe A#Ò8
°#&. 
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5. D-Phe(−1) ´b©§©²OÉ, Asp aC"%ÆÔ¸:8"
$mG&, D-Phe(−1) ´Ó¤n8x}# D-Phe(1) "$ |j?




6. D-Phe(−1) ¡Ø	µÓ¤Â©cy##, 
SSTR «Qf, *40+)/5,-"©²DO$
É&%DXLË£Ò8¡V&.  in vivo 	, O$É
& D-Phe(−1) ;ÅË£µ	È®!%°
#&, µu`³Ó¤p¬^8	% °#&. 
 
 
 <6, ¹±Õ´Ó¤?J, µÓ¤Z[











 NMR Hb@Rq#ŌÔ"$, ēĜǲÏ JEOL JNM-ECA-500 (500 MHz) Hb
@RqiuMu2ţ. 1H-NMR Hb@Rq#ªÒF]R$, ŌÔŎÎ 
 CDCl3 2ţÇ¶"$, PRoiNqFot2Ǜĩō  # 
d 2 ppm ƶŴ. , ŌÔŎÎ  CD3OD 2ţÇ¶"$ 
CD2H-OD (3.31 ppm), DMSO-d6 2ţÇ¶"$ CD2H-SO-CD3 (2.49 ppm) 2
ĩō . 13C-NMR Hb@Rq#ªÒF]R$, ŌÔŎÎ  CDCl3 2
ţÇ¶"$ CDCl3 (77.0 ppm), DMSO-d6 2ţÇ¶"$ (CD3)2SO (39.5 
ppm) 2ĩō . FATq#Ìǡê$, s: singlet, d: doublet, t: triplet, q: quartet, 
m: multiplet, br: broad #ŧ´2ţŴ. H\tƏ¶Ôč$ J  (Hz) 
ƶŴ. FATq#çß$ 1H-1H-COSY Hb@Rq"ÆÕĒ. 




 ġţưà@sfRAo]6u (TLC) $, Merck TLC Silica gel 60F254 2ţ
. Fp<Cq<oh@sfRAo]6u"$¿Ôű ǧğªÒ silica 
gel 60N (spherical, neutral; 63−210 µm) 2ţ. ]oOFlFp<Cq<o
h@sfRAo]6u"$¿Ôű ǧğªÒ  silica gel 60N (spherical, 
neutral; 40−50 µm) 2ţ. 
 Ǿǖń@sfRAo]6u (HPLC) ţǔű C18 Fp<Cq<oh 
 Cosmosil 5C18-AR-II (ġĕ; 4.6 × 250 mm ,% ²ĕ; 10.0 × 250 mm, 
Nacalai Tesque) 2ţ. 
 
 HPLC "$, Ĭ# 4 #FHPh2ţ.  
 
(1) Shimadzu LC-6A (pump), Shimadzu SCL-6B (system controller), Shimadzu 
SPD-6A (detector), Shimadzu C-R6A (recorder) 
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(2) Shimadzu LC-10ADvp (pump), Shimadzu SCL-10Avp (system controller), 
Shimadzu SPD-10Avp (detector), Shimadzu C-R8A (recorder) 
(3) Shimadzu LC-20AD (pump), Shimadzu SPD-20A (detector), Shimadzu C-
R8A (recorder) 
(4) Hitachi L-2130 (pump), Hitachi L-2400 (detector), Hitachi D-2500 (recorder) 
 
 !, Ÿ©ű"$äǉ# HPLC AruS#ƹ»2#''ţ. HPLC "





 ċÚƒǢ#ŌÔ"$, Aloka ŵƹ RLC-551, ARC-380 ,% Perkin Elmer 







 Jo7R1ǘ"$ºƈƱáĦ Celite545 2ţ. 
 Fmoc 5gXǟǃÛ,%  H-Thr(t-Bu)-ol-2-@ssRpNqĪƣ  (0.63 
mmol/g) $ŉǐªÒáĦ#ƹ»2ţ. 
 ċÚõ·Ƌ 111InCl3 (74 MBq) $ēĜiG]6GO@Hŵ,.ǌ. 
[125I]Tyr11-somatstatin-14 (NEX446) $, Perkin Elmer ŵ,.ǌ. 
 JqsuH5JPuRƪǲĴľ©"$, ý  Separax-SP (Joko) 2ţ
,ĩǇb_NS#ċÚªÒŭƈê#ŌÔĕ"$, veronal ƓƵń (7;tíê 





 oORƫƬ3ƌơ AR42J ģ (ATCC CRL-1492) $ DS ]4ufY7;B
g<qģëŵ,.ǌ. AR42J ƌơ#Åǻ"$ºƈƱáĦģëŵ# 
Ham’s F-12K ÅÂ2ţ. 


































3, 6-di-azaoctanedioate (2) 
 5qDtǱ¾Ĵy, G:NrtRp5gt (5.34 mL, 50.0 mmol) 2 CH2Cl2 
(500 mL) "Ŏƻ, Ķyĉþ. 15 ð, CF3CO2C2H5 (6.57 mL, 55.0 
mmol, 1.1 eq.) 2<UlruFmt",.°óń"Őyð"Öŋ& Ĕŋ
ĉþ. 12 ĕǦð, ňÀyŎÎ2Ŧ¯. İŊ2CH3CN (300 mL) "
Ŏƻ, DIPEA (25.0 mL, 180 mmol, 1.2 eq.) 2¨
, Ķyĉþ. 30 ð, 
BrCH2CO2t-Bu (25.0 mL, 180 mmol, 1.2 eq.) 2¨
ð"Öŋ& Ĕŋ 2 ē
Ǧĉþ. ňÀyŎÎ2Ŧ¯, İŊ2 AcOEt   H2O ǜ. ęī
à2ǺºǷÉĵĿŁ, Řĵ Na2SO4 |řð"ŎÎ2ňÀyŦ¯. 
İŊ2Fp<Cq<oh@sfRAo]6u (Hexane : AcOEt = 6 : 1 → 4 : 1) 
ƅƹ, ĩǶª¶Ś(26.0 g, 44.5 mmol, 89%) 2ŘƯĺŜŚǋ ñ. 
1H-NMR (CDCl3, 500 MHz) d 8.65 (1H, s), 3.45 (4H, s), 3.37–3.34 (2H), 3.29 (2H, s), 
2.87–2.84 (4H), 2.79–2.76 (2H), 1.46–1.45 (27H); 13C-NMR (CDCl3, 125 MHz) d 170.9, 
170.4, 157.3 (q, J = 37.0 Hz, -COCF3), 116.1 (q, J = 287.3 Hz, -COCF3), 81.4, 81.2, 
56.0, 55.7, 51.2, 50.0, 49.4, 38.5, 28.1, 14.1; ESI-LRMS m/z 542 [(M + H)+]; ESI-
HRMS calcd. for C24H43F3N3O7 542.3053, found 542.3057 [(M + H+)]. 

xƿī¼QuM,%ĎŝƿǏ 47) # 1H-NMR QuM-·Ô. 
 
 
Di-tert-butyl 3, 6-bis-((tert-butoxycarbonyl)methyl)-9-(2-trifluoroacetyl)-3, 6, 9- 
triazaundecanedioate (3) 
 5qDtǱ¾Ĵy, ª¶Ś 2 (5.84 g, 10.0 mmol) 2 DMF (100 mL) "Ŏƻ, 
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Ķyĉþ. 20 ð, NaH (60% in mineral oil; 600 mg, 15.0 mmol, 1.5 eq.) 
  BrCH2CO2t-Bu (2.7 mL, 20 mmol, 2.0 eq.) 2¨
, Ķy 30 ĉþð"Ö
ŋ& Ĕŋĉþ. 2.5 ĕǦð, Ķy" sat. NH4Cl aq. °ó2ĭ, 
AcOEt   H2O ǜ. ęīà2ǺºǷÉĵĿŁ, Řĵ Na2SO4 |
řð"ŎÎ2ňÀyŦ¯.  İŊ2Fp<Cq<oh@sfRAo]6
u (Hexane : AcOEt = 6 : 1) ƅƹ, ĩǶª¶Ś (4.25 g, 6.48 mmol, 65%) 2
ŘƯĺŜŚǋ ñ. 
1H-NMR (CDCl3, 500 MHz) d  4.29 (1H, d, J = 1.1 Hz), 4.17 (1H, s), 3.57–3.55 (2H), 
3.43 (4H, d, J = 2.3 Hz), 3.30 (2H, d, J = 4.0 Hz), 2.85–2.91 (2H), 2.79–2.76 (4H), 
1.47–1.45 (27H); ESI-LRMS m/z 678 [(M + Na)+]; ESI-HRMS calcd. for 
C30H52F3N3O9Na 678.3553, found 678.3558 [(M + Na+)]. 
 
xƿī¼QuM,%ĎŝƿǏ 47) # 1H-NMR QuM-·Ô. 
 
 
1-Benzyl tert-butyl 3, 6, 9-tris((tert-butoxycarbonyl)methyl)-3, 6, 9-triaza- 
undecanedioate (4) 
 5qDtǱ¾Ĵy, ª¶Ś 3 (984 mg, 1.50 mmol) 2 t-BuOH (10 mL) "Ŏƻ
, ĶyŘĵ[SoGt (4.8 mL, 150 mmol, 100 eq.) 2¨
ĉþ. 3 ĕ
Ǧð, °óń" AcOEt   sat. NH4Cl aq. 2¨
ǜ, ęīà2ǺºǷÉĵ
ĿŁ, ŘĵNa2SO4 |řð"ŎÎ2ňÀyŦ¯. İŊ2 DMF (10 
mL) "Ŏƻ, DIPEA (510 µL, 3.00 mmol, 2.0 eq.) 2¨
Ķyĉþ. 15 
ð, BrCH2CO2Bn (471 µL, 3.00 mmol, 2.0 eq.) 2¨
ð"Öŋ& Ĕŋ 16 
ĕǦĉþ. °óń" AcOEt   sat. NH4Cl aq. 2¨
ǜ, ęīà2Ǻ
ºǷÉĵĿŁ, Řĵ Na2SO4 |řð"ŎÎ2ňÀyŦ¯. İŊ2
Fp<Cq<oh@sfRAo]6u (CHCl3 : MeOH = 99 : 1) ƅƹ, ĩǶ
ª¶Ś (866 mg, 1.22 mmol, 81%) 2ŘƯĺŜŚǋ ñ. 
1H-NMR (CDCl3, 500 MHz) d 7.36–7.35 (5H), 5.14 (2H, s), 3.63 (2H, s), 3.46–3.44 
(6H), 3.34 (2H, s), 2.86–2.75 (8H), 1.45–1.44 (36H); 13C-NMR (CDCl3, 125 MHz) d 
171.2, 170.9, 170.6, 170.5, 135.7, 128.5, 128.3, 128.2, 128.1, 80.8, 80.7, 80.6, 66.0, 
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56.0, 55.8, 55.2, 53.4, 52.8, 52.8, 52.3, 52.2, 28.1, 28.1; ESI-LRMS m/z 708 [(M + H)+]; 
ESI-HRMS calcd. for C37H62N3O10 708.4435, found 708.4437 [(M + H+)]. 
 
xƿī¼QuM,%ĎŝƿǏ 47) # 1H-NMR QuM-·Ô. 
 
 
1-tert-Butyl hydrogen 3, 6, 9-tris((tert-butoxycarbonyl)methyl)-3, 6, 9-triaza- 
undecanedioic acid (mDTPA) 
 ª¶Ś 4 (503 mg, 711 µmol) 2 AcOEt (7 mL) "Ŏƻ, Pd/C (168 mg, ca. 30 
wt%) 2¨
ĵƋ=H2ņ¨, 6 ĕǦĉþ. °óń2Jo7R1ǘ1
ń#ŎÎ2ňÀyŦ¯. İŊ2Fp<Cq<oh@sfRAo]6u 
(CHCl3 : MeOH = 97 : 3) ƅƹ, ĩǶª¶Ś (411 mg, 665 µmol, 94%) 2ŘƯ
ĺŜŚǋ ñ. 
1H-NMR (DMSO-d6, 500 MHz) d 8.31 (s, 1H), 3.38–3.32 (10H), 2.69–2.65 (8H), 1.39 
(s, 36H); 13C-NMR (CDCl3, 125 MHz) d 172.5, 170.3, 170.2, 80.2, 80.1, 79.2, 55.7, 
55.6, 55.0, 52.0, 51.7, 27.8; ESI-LRMS m/z 618 [(M + H)+]; ESI-HRMS calcd. for 






 H-Thr(t-Bu)-ol-2-@ssRpNqĪƣ (0.63 mmol/g) 2ū®ď", Ǥǈ
Fmoc 5gXǟǃÛ2ţy"ŴƔ¶ ƥǈĊ2Ɨ.ǒ "
,., Ǥǈb_NSǤ2Īƣx"ħƃ. 
 
[1] Ǥǈ Fmoc 5gXǟǃÛ (2.5 eq.), DIC (2.5 eq.) ,% HOBt·H2O 
(2.5 eq.) 2¨
, DMF { 1.5 ĕǦĂ 	ĉþ.  
[2] 20% \bpGt¸ę DMF Ŏń2Īƣ"¨
, 20ǦĂ 	ĉþð", 
DMF Īƣ2Ɨ.ǒĿŁ. 
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 Ɣ¶°ó#ƍŗ$, Ă 	ĉþð#Īƣ#vǛ2Ą², Kaiser ǁǽǬõ
2Ŵ 2+ĸÔ. ƥǈĊƍ}ð"$ Kaiser ǁǽǭõ !
/ 2ųǂ. 
 
 !, ǈb_NSĪƣ#ħƃ"ţǤǈ Fmoc 5gXǟǃÛ"
$ , Fmoc-Cys(Acm)-OH, Fmoc-Thr(Ot-Bu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-D-
Trp(Boc)-OH, Fmoc-Phe-OH, Fmoc-D-Phe-OH, Fmoc-Asp(Ot-Bu)-OH 2ţ. 
 
GHq]6SƏ¶#ħƃ
 ǜ¡2ħƃǈb_NSĪƣ2 DMF "øœ, Tl(tfa)3 (2 eq.) 2¨

Ă 	ĉþ. 1 ĕǦð, DMF ,% CH2Cl2Ɨ.ǒĪƣ2ĿŁ. 
 
mDTPA #Ɣ¶ 
 Tl(tfa)3 ŠǤǈb_NSĪƣ  mDTPA (2.5 eq.), DIC (2.5 eq.) 
,% HOBt·H2O (2.5 eq.) 2Ņ¶, DMF { 1.5 ĕǦOĉþ. °ó




 b_NSǤ N ěż" mDTPA Ɣ¶šŜǤǈb_NSĪƣ"
ĶyN;5ULuq (150 µL) ,% TFA (3 mL) 2¨
, Öŋ 2.5 ĕ
ǦĂ 	ĉþ. °óń{-Īƣ21ǘ",.ǫ¯, 1ń2Ķ.
1ń"ĶG:Nq:uPq2¨
Ƅb_NSŢùŚ2ġð", 6 
mol/L ÉǟA5UGtĵŎńü. ĵà2G:Nq:uPq 2 ½Ŀ
Ł, ňÀyŎÎ2ŔƔ, Ðï 0.45 µm #ĵƇ]6qMu1ǘ. 
#Ŏń2ǔű HPLC ", 254 nm jUMu, ůŭª¶Ś2¸)]o@
Fmt2½± , Ə|ř/   DTPA-D-Phe1-octreotide, DTPA-Asp1-
octreotide ,% DTPA-Asp0-D-Phe1-octreotide 2ŬƯƚĳŜŚǊ 0
0 31%, 38% ,% 42% #±Şñ.  
 ! , ĩǇ¥Ǽb_NS#  HPLC ġ,%²"$ , Ŏń 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0.1% TFA ĵŎń  CH3CN 2ţ, y#ĝÕĒ. 
 
Table 8. Conditions and gradient programs for RP-HPLC analyses and purification. 
 
   • Column: Cosmosil 5C18-AR-II  
            (analysis: 4.6 × 250 mm, preparative: 10.0 × 250 mm) 
   • Flow rate: 1.0 mL/min (analysis), 5.5 mL/min (preparative) 




DTPA-D-Phe1-octreotide, ESI-LRMS m/z 1394 [(M + H)+]; ESI-HRMS calcd. for 
C63H88N13O19S2 1394.5761, found 1394.5755 [(M + H+)].  
DTPA-Asp1-octreotide, ESI-LRMS m/z 1362 [(M + H)+]; ESI-HRMS calcd. for 
C58H84N13O21S2 1362.5346, found 1362.5342 [(M + H+)]. 
DTPA-Asp0-D-Phe1-octreotide, ESI-LRMS m/z 1509 [(M + H)+]; ESI-HRMS calcd. for 





Ž 1 Ż Ž 3 Ƃ"ǧ/Õǽ 
 
DTPA-octreotide ǃÛ# 111In ĩǇ 
 DTPA Ɣ¶b_NS (10 µg), @:tǟwTRp8h (4.91 mg), @:tǟ 
(0.37 mg), 7XFRuq (10.0 mg) ,%CtNGtǟ (2.0 mg) Ŏƻ
Ǎƈĵ (250 µL) 2Ə|ř, 111In ĩǇ>OR2ƹ. 
 ñ-0>OR" 111InCl3 # 0.02 N ÉǟŎń (1 mL) 2¨
, Öŋ 1 ĕ
Ǧ7t>lauR, ůŭ / 111In ĩǇb_NS2ñ. !, ċÚªÒ
ŭƈê#ŌÔ$JqsuH5JPuRƪǲĴľ©,% TLC (MeOH : 10% 
NH4Cl aq. = 1 : 1) ",.ƀ, 10#Ç¶+ 95% x#ċÚªÒŭƈ
ê2ǂ*. 
 !, ƌơÕǽ#Ǯ"$, °óń"ǴċÚõ# 115InCl3 (1 eq.), EDTA (ĘƍŔ
ê 10 mM), CaCl2 (ĘƍŔê 10 mM) 2ǵ"¨
, 00 30 ǦÖŋ7




 µ 111In-DTPA ĩǇb_NS (0.2 kBq) 2JqsuH5JPuRƪ"Èå, 




Ž 1 Ż Ž 4 Ƃ"ǧ/Õǽ 
 
Eg`k 
 oORƫƬ3ŤĞ AR42J ƌơģ#Åǻ"$, Ǵª 10% FBS ,
% 100 IU/mL bUFpt-100 µg/mL HRr_Rf7Ft2¸ę/ Ham’s F-





 Åǻ AR42J ƌơ2 0.25 w/v% Rp_Ft–1 mM EDTAŎń§ǰ, ½±
. ƌơ2 10 mmol/L MgCl2, 10 µmol/L YFRoFt2¸ę/ 10 mmol/L 
Tris-HCl ƓƵń (pH 7.4) "øœ, ĶxepRstcjGT7Eu (PT 10-
35 <, Kinematica) j , DCY^ 5 d9 3 6+,& 	. ñ
-0øœń2 4 °C  10 Ǧ 39,000 × g ǚĹ, ñ-0brOR2x
Ǔ#ƓƵń 1 êĿŁð", êøœń . øœń{#MtZ@ǋ
Ŕê$ Bradford ļ2ţŌÔ. 
 ŌÔ$ triplicate ÕĒ. MtZ@ǋǢ  30 μg "űî/ AR42J 
ƌơ#ƌơƪøœń2 1% BSA, 5 mmol/L MgCl2, 200 KIU/mL 5_sNUt, 
0.02 mg/mL YFRoFt, 0.02 mg/mL ]Oª]9UqiNqHqcUq2¸
ę/ 50 mmol/L HEPES ƓƵń (pH 7.4) # 250 µL "øœ. #ƌơƪ
øœń", 10−12–10−6 mol/L#Ŕê 115In ǜb_NS  [125I]Tyr11-somatostatin-
14 (0.75 kBq) 2Ņ¶, 30 °C 7t>lauR. 25 ð, 0.1% ep:N
rt7gtĵŎń" 3 ĕǦxŃő=oHƕƑ1Ɖ (Whatman, GF/B) 2
ţ°óń2ôǖ¹ì1ǘ, Ű"1Ɖ2 1% BSA ¸ę# PBS(−) 2 mL 
 5 ½ĿŁ. #ŕƉ#ċÚƢ2 g <8tMuŌÔ. ċÚƢ#Ǵ
śŨŭƏ¶Ǣ$, 10−4 mol/L # octreotide ÑÁyƌơƪ27t>lauR
Ǯ"ñ-01Ɖ#ċÚƢ , ǁǽª¶Ś#ÑÁyñ-0ċÚƢ #
ã2śŨŭƏ¶Ǣ . 00#Ŕê",/ǁǽª¶Ś#śŨŭƏ¶Ǣ
2, [125I]Tyr11-somatostatin-14 #śŨŭƏ¶"Ù/ú¤ţ (%)  ƀ




 12-well plate " AR42J ƌơ2 1.0 × 105 cells ĈŹ, 37 °C, 5% CO2 ĝ
y" 2 ēǦÅǻ. ÅÂ2ǫ¯, PBS(−) 1 mL ĿŁð, 0.1% FBS 
2¸ę/ Ham’s F-12K ÅÂ (500 µL) 2ņ¨, 2 ĕǦ_r7t>lauR
. 1 pmol # D-Phe(1), Asp(1) '$ Asp(0) Ŏƻ 0.1% FBS ¸ę 
Ham’s F-12K ÅÂ (500 µL) 2ņ¨, 0.5, 1, 2, 4 ĕǦ7t>lauR. Å
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Â2ǫ¯, 10% FBS ¸ę Ham’s F-12K ÅÂ 1 mL, PBS(−) 1 mL ƌơ2ǵ
ĬĿŁ, 0.1% Triton-X ¸ę 0.3 mol/L NaOH ĵŎń (1 mL) ƌơ2Ŏƻ




 12-well plate " AR42J ƌơ2 5.0 × 105 cells ĈŹ, 37 °C, 5% CO2 ĝ
y" 2 ēǦÅǻ. ÅÂ2ǫ¯, PBS(−) 1 mL ĿŁð, 0.1% FBS 
2¸ę/ Ham’s F-12K ÅÂ (500 µL) 2ņ¨, 2 ĕǦ_r7t>lauR
. 1 pmol # Asp(0)  ǴċÚõ octreotide (ƍŔê 10−10–10−6 mol/L) 2·ĕ
"ņ¨ 4 ĕǦ7t>lauR. ÅÂ2ǫ¯, 10% FBS ¸ę Ham’s F-
12K ÅÂ  1 mL, PBS(−) 1 mL ƌơ2ǵĬĿŁ , 0.1% Triton-X ¸ę  0.3 
mol/L NaOH ĵŎń (1 mL) ƌơ2Ŏƻ. ñ-0ƌơŎƻń"




Ž 1 Ż Ž 5 Ƃ"ǧ/Õǽ 

f8HƳŒ{#ÓÔõ
 G:Nq:uPqȀǝy, 6 Ǘȁ#ǯõ ddY f8H#òƬ-, `Zpt2
ÈåĽÚſ2ţĄƳ, 4 °C  30 Ǧ, 1,200 × g #ǚò",.Ƴ
Œ2ǅƹ. ñ-0ƳŒ (400 µL) " 111In ĩǇb_NS (40 ng, 592 kBq, 8 
µL) 2¨
, 37 °C 7t>lauR. 1 ,% 3 ĕǦð", JqsuH
5JPuRƪǲĴľ©  (1 mA/cm, 40 min) ,% TLC (MeOH : 10% NH4Cl aq. 
= 1 : 1) ƳŒ#ċÚƢ2ŌÔ, ĚÊª#Ǣ2ƀ. ', 7t>la
uR 3 ĕǦð#ƳŒ2ťÏǢ 10,000 #@7n5h (Amicon-4) n5





 5 Ǘȁ#ǯõ ddY f8H2Õǽ"/' 1 ǗǦƾƮ. Õǽĕ"
$ǡ 28–30 g #f8H 5 ¬2 1 ƙ , ǹď,%Ǹĵ$ƭŤĆ² 
 . f8H"  20 mmol/L HEPES ƓƵŢŠǷÉĵ  (pH 7.4) "Ŏƻ  D-
Phe(1)  '$ Asp(0) #Ŏń (0.1 µg, 5.6 kBq, 100 µL) 2ÝǳƤ,.ûz. 
ûz 10 , 0.5, 1, 3, 6, 24 ĕǦð"G:Nq:uPqȀǝy, `Zpt2Èå
ĽÚſ2ţòƬ-#ĄƳ",.Ʈį, Ƴń,%ǧòƬ¼ 
(ƜƬ, ƧƬ, ÜƩ, ÍƩ, Ɵ, ƦƬ, ƫƬ, ƞ, òƬ, žƛ) 2Ą². Ƴń,
.ƳŒ2ǅƹ, ǧòƬ¼ "ǡǢ2ŌÔð, g <8tMu"ċÚƢǢ
2ŌÔ. !, Ɵ, ÜƩ, ÍƩ#ØŚ$².1, #''ŌÔ. 
ŌÔƬ¼#ċÚƢǢ$, ƎƖǡǢ# 1 g ."ąƀ %ID/g  ĩ
ōª. 
 ', 24 ĕǦƙ#f8H"$, ǆCuG (iMdp< MM Ä, ģ
ëŵH?kfCt) ǹƝ, ûzŰð- 24 ĕǦð'"ăĻ0Þ
 Ɔ2Ą², 0-#ċÚƢǢ2ŌÔ %ID  ƶ. 
 
oORƫƬ3jQqf8H#ƹ
 8 Ǘȁ#ǯõVuSf8H (Balb-c, nu/nu) 2Õǽ"/' 1 ǗǦƾƮ
. Åǻ AR42J ƌơ#č2ƳşƼƀĠŌÔ 5.0 × 106 cells/0.1 mL"
!/,	" PBS(−) æǠ, ƌơøœń2ǅƹ. #øœń# 0.1 mL 




 VuSf8H" AR42J ƌơ2ŸĤð 10–14 ēů", 20 mmol/L HEPES ƓƵ
ŢŠǷÉĵ (pH 7.4) "Ŏƻ D-Phe(1) '$ Asp(0) #Ŏń (0.1 µg, 5.6 
kBq, 100 µL) 2ÝǳƤ,.ûz. ûz 1, 3, 24 ĕǦð"7L]qot¹
ȀǝyòƬ-#ĄƳ",.Ʈį, Ƴń,%ǧòƬ¼ (ƜƬ, ƧƬ, 
ÜƩ, ÍƩ, Ɵ, ƦƬ, ƫƬ, ƞ, òƬ, žƛ, ƨũ) 2Ą². Ƴń,.ƳŒ
2ǅƹ, ǧòƬ¼#Ǣ'$vǛ"ǡǢ2ŌÔð, g <8tM
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u"ċÚƢǢ2ŌÔ. !, Ɵ, ÜƩ, ÍƩ#ØŚ$².1, #
''ŌÔ. ', 24 ĕǦƙ#f8H"$, ǆCuG (iMdp<
MM <, ģëŵH?kfCt) ǹƝ, ûzŰð- 24 ĕǦð'"ă
Ļ0Þ Ɔ2Ą², 0-#ċÚƢ2ŌÔ. 




 In vitro Õǽñ-0ƏĢ$, éÃ ± ĩōǄã (SE) Ŵ, in vivo Õ
ǽñ-0ƏĢ$, éÃ ± ĩōã (SD) Ŵ.  
 Asp(0) #ƌơ²Ǒ(Ǩ×Õǽ$, vǜƘČġ (one-way ANOVA) #ð, 
Dunnett #ĥÔ2ÕĒ. 





















Ž 2 Ż Ž 2 Ƃ"ǧ/Õǽ 
 
111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide(D-Phe(−1)) #¶ù 
 D-Phe(−1) $, D-Phe(1) #Ç¶ ·Ĩ" mDTPA   Fmoc ¿ű¶ùļ2£
ţĩǇ¥Ǽb_NS DTPA-D-Phe−1-Asp0-D-Phe1-octreotide 2 27% #±
Şñð, ĩǇ>OR2ƹ, 111InCl3 # 0.02 N ÉǟŎń2ņ¨/ 
¶ù. !, ċÚªÒŭƈê#ŌÔ$JqsuH5JPuRƪǲĴľ©
ļ,% TLC (MeOH : 10% NH4Cl aq. = 1 : 1) ",.ƀ, 10#Ç¶
+ 95% x#ċÚªÒŭƈê2ǂ*. 
 !, ĩǇ¥Ǽb_NS DTPA-D-Phe−1-Asp0-D-Phe1-octreotide # HPLC 




Table 9. Conditions and gradient programs for RP-HPLC analysis and purification. 
 
• Column: Cosmosil 5C18-AR-II (analysis: 4.6 × 250 mm, preparative: 10.0 × 250 mm) 
• Flow rate: 1.0 mL/min (analysis), 5.5 mL/min (preparative) 




DTPA-D-Phe−1-Asp0-D-Phe1-octreotide, ESI-LRMS m/z 1678 [(M + Na)+]; ESI-HRMS 




 Ž 1 ŻŽ 3 Ƃ#đļ ·Ĩ"JqsuH5JPuRƪ" 111In ĩǇb_
NS2Èå, pH 5.0, 6.0 7.0, ,% 7.4 # 20 mmol/L ptǟƓƵń{, 1.0 
mA/cm  40 Ǧľ©. 
 
 
Ž 2 Ż Ž 3 Ƃ"ǧ/Õǽ 
 
ƳŒ{ÓÔõ
 Asp(0) #Ç¶ ·Ĩ", f8HĐǿƳŒ (400 µL) " D-Phe(−1) (40 ng, 592 
kBq) 2ņ¨,  37 °C 7t>lauR. 1, 3 ĕǦð"JqsuH5J




 Asp(0) #Ç¶ ·Ĩ" 1 ƙ 3–4 ¬ #ǯõ ddY f8H" D-Phe(1) '
$ D-Phe(−1) (0.1 µg, 5.6 kBq) 2ÝǳƤ,.ûz. ûz 1, 3, 24 ĕǦð"
G:Nq:uPqȀǝyòƬ-ĄƳ, ǧòƬ¼2Ą²ð, ċÚƢ









 5qDtǱ¾Ĵy, mDTPA (62 mg, 0.1 mmol), D-Phe-Otert-Bu·HCl (26 mg, 0.1 
mmol), EDCI (38 mg, 0.2 mmol, 2 eq.),  HOBt·H2O (31 mg, 0.2 mmol, 2 eq.) ,%
Rp:Nq5gt (17 µL, 0.12 mmol, 1.2 eq.) 2 CH2Cl2 (1 mL) "Ŏƻĉþ
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. 2 ĕǦð, °óń" AcOEt   sat. NaHCO3 aq. 2¨
ǜ, ęīà2
ǺºǷÉĵĿŁ, Řĵ Na2SO4 |řð"ŎÎ2ňÀyŦ¯. İŊ
2Fp<Cq<oh@sfRAo]6u (CHCl3 : MeOH = 99 : 1) ƅƹ, ĩ
Ƕª¶Ś (66 mg, 80.4 µmol, 80%) 2ŬƯ¿ ñ.  
1H-NMR (500 MHz, CDCl3) d 7.95 (1H, d, J = 8.6 Hz), 7.29–7.20 (5H), 4.69 (1H, q, J 
= 7.5 Hz), 3.48–3.04 (12H), 2.80–2.69 (8H), 1.45 (36H, s), 1.39 (9H, s); 13C-NMR (125 
MHz, CDCl3) d 171.1, 170.7, 170.5, 170.4, 170.3, 136.7, 129.3, 128.2, 126.7, 81.6, 81.1, 
80.7, 80.7, 58.2, 56.5, 55.9, 55.8, 53.4, 53.0, 52.9, 52.3, 52.0, 37.8, 28.1, 28.1, 27.9; 
ESI-LRMS m/z 843 [(M + Na)+]; ESI-HRMS calcd. for C43H72N4O11Na 843.5095, found 
843.5091 [(M + Na)+]. 
 
DTPA-D-Phe-OH 
 ª¶Ś 5 (59 mg, 71.9 µmol) "Ķy5ULuq (250 µL), TFA (5 mL) 2
ǵĬ¨
Öŋ"Ĕŋð" 3.5 ĕǦĉþ. ňÀyŎÎ2Ŧ¯, İŊ
"ĶG:Nq:uPq (20 mL) 2¨
ð, Öŋ 5 Ǧ, 100 × gǚò
, ƄŢùŚ2ñ. xŇ2ǫ¯, İŊ2 0.1% TFA ĵŎń"Ŏƻ, 0.45 µm 
#ĵƇ]6qMu1ǘð"  C18 ǔű  HPLC (5–50% CH3CN in 0.1% 
TFA/H2O) ƅƹ, Ə|ř, ĩǶª¶Ś (27 mg, 50 µmol, 70%) 2ŬƯƚĳ
Ŝ¿ ñ. 
1H-NMR (500 MHz, CD3OD) d 7.30–7.19 (5H), 4.72 (1H, q, J = 4.6 Hz), 4.32 (2H, dd, 
21.8, 17.8 Hz), 3.61 (4H, s), 3.47–2.96 (13H); 13C-NMR (125 MHz, CD3OD) d 174.8, 
174.5, 174.2, 172.9, 169.3, 138.5, 130.3, 129.6, 127.9, 57.9, 56.2, 55.8, 54.9, 54.4, 54.3, 
54.0, 50.9, 50.6, 49.6, 38.2; ESI-LRMS m/z 541 [(M + H)+]; ESI-HRMS calcd. for 
C23H33N4O11 541.2146, found 541.2142 [(M + H+)]. 
 
DTPA(tert-Bu)4-Asp(OBn)-Otert-Bu (6) 
 5qDtǱ¾Ĵy, mDTPA (247 mg, 0.4 mmol), Asp(OBn)O-tert-Bu·HCl (126 mg, 
0.4 mmol), EDCI (115 mg, 0.6 mmol, 1.5 eq.), HOBt·H2O (92 mg, 0.6 mmol, 1.5 eq.) 
,%Rp:Nq5gt (58 µL, 0.42 mmol, 1.4 eq.) 2 CH2Cl2 (5 mL) "Ŏƻ
Öŋĉþ. 2.5 ĕǦð, b20 AcOEt  sat. NaHCO3 aq. 2¨

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ǜ, ęīà2ǺºǷÉĵĿŁ, Řĵ Na2SO4 |řð"ŎÎ2ňÀy
Ŧ¯. İŊ2Fp<Cq<oh@sfRAo]6u (Hexane : AcOEt = 3 : 
2) ƅƹ, ĩǶª¶Ś (312 mg, 0.354 mmol, 89%) 2ŬƯ¿ ñ. 
1H-NMR (500 MHz, CDCl3) d 8.24 (1H, d, J = 8.0 Hz), 7.36–7.29 (5H), 5.17 (1H, d, J 
= 12.0 Hz), 5.09 (1H, d, J = 12.0 Hz), 4.77 (1H, m), 3.43–3.26 (10H), 2.98–2.77 (10H), 
1.45 (36H, s), 1.41 (9H, s); 13C-NMR (125 MHz, CDCl3) d 171.4, 170.8, 170.6, 170.5, 
170.4, 169.4, 135.7, 128.5, 128.4, 128.3, 82.2, 81.3, 80.9, 80.8, 66.6, 58.3, 56.6, 56.0, 
55.9, 53.0, 52.5, 52.2, 49.0, 36.7, 28.2, 27.9; ESI-LRMS m/z 879 [(M + H)+]; ESI-
HRMS calcd. for C45H75N4O13 879.5331, found 879.5330 [(M + H)+]. 
 
DTPA-Asp(OBn)-OH (7) 
 ª¶Ś 6 (50 mg, 56.8 µmol) "Ķy5ULuq (150 µL), TFA (3 mL) 2
ǵĬ¨
ð"Öŋ"Ĕŋ 2.5 ĕǦĉþ. ňÀyŎÎ2Ŧ¯, İŊ
"ĶG:Nq:uPq (20 mL) 2¨
ð, Öŋ 5 Ǧ, 100 × gǚò
, ƄŢùŚ2ñ. xŇ2ǫ¯, İŊ2 0.1% Rp]q;sǞǟĵŎń"
Ŏƻ , 0.45 µm #ĵƇ]6qMu1ǘð"  C18 ǔű  HPLC (10–55% 
CH3CN in 0.1% TFA/H2O) ƅƹ, Ə|ř, ĩǶª¶Ś (27 mg, 44.5 µmol, 
78%) 2ŬƯƚĳŜ¿ ñ. 
1H-NMR (500 MHz, CD3OD) d 7.36–7.30 (5H), 5.14 (2H, s), 4.84–4.82 (1H, m), 4.36 
(2H, d, J = 1.7 Hz), 3.62–3.45 (12H), 3.18–3.14 (4H), 3.00 (1H, dd, J = 4.6, 16.6 Hz), 
2.93 (1H, dd, J = 4.6, 16.6 Hz); 13C-NMR (125 MHz, CD3OD) d ; 174.9, 174.2 173.5, 
173.0, 172.1, 169.2, 137.3, 129.6, 129.3, 67.8, 58.2, 56.4, 55.9, 54.5, 54.4, 54.3, 51.0, 
50.6, 50.1, 49.6, 36.9; ESI-LRMS m/z 599 [(M + H)+]; ESI-HRMS calcd. for 
C25H35N4O13 599.2201, found 599.2201 [(M + H)+]. 
 
DTPA-Asp-OH. 
 ª¶Ś 7 (43 mg, 71.8 µmol) 2 MeOH (1 mL) "Ŏƻ, 10% Pd(OH)2 (43 mg) 
2¨
PV]4	, 4.5 H98m	. °óń2Jo7R1ǘ1ń#
ŎÎ2ňÀyŦ¯, ĩǶª¶Ś (36 mg, 70.8 µmol, 99%) 2ŘƯ¿ 
ñ.  
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1H-NMR (500 MHz, CD3OD) d 4.77 (1H, t, J = 6.3), 4.27 (2H, br, s), 3.97 (1H, s), 3.71–
3.46 (12H), 3.18–3.17 (4H), 2.92–2.85 (2H); 13C-NMR (125 MHz, CD3OD) d 175.0, 
174.3, 174.2, 173.9, 173.8, 173.1, 169.7, 58.3, 56.9, 56.3, 56.0, 55.2, 54.4, 53.5, 51.1, 
50.7, 50.1, 49.6, 36.6; ESI-LRMS m/z 509 [(M + H)+]; ESI-HRMS calcd. for 
C18H29N4O13 509.1731, found 509.1735 [(M + H+)]. 
 
DTPA-D-Phe-Asp-OH 
 Fmoc-Asp(Ot-Bu)-Wang Īƣ  (50 mg, 42 µmol) "  20% \bpGt¸ę  
DMF Ŏń2¨
 20 ǦĂ 	ĉþ. Īƣ2 DMF "ĿŁ
ð", Fmoc-D-Phe-OH (41 mg, 105 µmol, 2.5 eq.), mDTPA (74 mg, 120 µmol, 2.86 
eq.) #ǵ"Īƣxǜ¡2ǥ. Īƣ2 CH2Cl2 "ĿŁð", 
ňÀyvĖ|ř. Īƣ"Ķy5ULuq (150 µL), TFA (3 mL) 2ǵ
Ĭ¨
ð"Öŋ"Ĕŋ 2.5 ĕǦĉþ. b20[IG5
L;	, 0cl	. cl"-#-4U*)"%RQeS
K
A, 6 mol/L 1F'.Pi0\K	. PW"-
#- 2 6TN	, ?/3ia_J	, B= 0.45 µm P>(-!
5	A:X HPLC  (10–40% CH3CN in 0.1% TFA/H2O) ƅƹ, Ə|
ř, ĩǶª¶Ś ((13.5 mg, 20.6 µmol, 49%) 2ŬƯƚĳŜ¿ ñ. 
1H-NMR (500 MHz, CD3OD) d 7.29–7.19 (5H), 4.75 (1H, dd, J = 6.3, 9.2 Hz), 4.71 
(1H, t, J = 6.3), 4.34 (2H, s), 3.62 (4H, s), 3.48–3.33 (8H), 3.18–3.12 (3H), 3.05 (2H, 
m), 2.92 (1H, dd, J = 9.0, 13.7 Hz), 2.78–2.69 (2H); 13C-NMR (125 MHz, CD3OD) d 
174.9, 174.2, 174.0, 173.7, 173.2, 173.0, 169.4, 138.4, 130.5, 129.6, 128.0, 58.1, 56.4, 
55.9, 55.7, 54.7, 54.6, 54.2, 51.0, 50.8, 50.2, 49.7, 38.9, 36.8; ESI-LRMS m/z 656 [(M 
+ H)+]; ESI-HRMS calcd. for C27H38N5O14 656.2415, found 656.2419 [(M + H)+]. 
 
111In-DTPA-D-Phe-OH, 111In-DTPA-Asp-OH ,%  111In-DTPA-D-Phe-Asp-OH #
ǅƹ 
 50–100 µg #ĩǇ¥Ǽ2 50 mmol/L #ǞǟƓƵń (pH 5.5, 200 µL) "Ŏƻ
, 111InCl3 # 0.02 N ÉǟĵŎń (370 kBq) 2ņ¨, Öŋ 1 ĕǦ7t>l
auR. ċÚªÒŭƈê$, JqsuH5JPuRƪǲĴľ©,%ǔű 
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HPLC ,.ƀ. 
 -", 00# 111In ĩǇĩ»2ųǂ/*", ǴċÚõ 115In ǜ
  115In-DTPA-D-Phe-OH, 115In-DTPA-Asp-OH ,%  115In-DTPA-D-Phe-
Asp-OH 2¢Ǖǅƹ, xǓ# 111In ĩǇ #ǔű HPLC #·ĕġ2Õ
Ē.  
ESI-LRMS: 115In-DTPA-D-Phe-OH, calcd. for C23H30N4O11In; m/z 653, found 653 [(M 
+ H)+], calcd. for C23H28N4O11In; m/z 651, found 651 [(M − H)−]. 115In-DTPA-Asp-OH, 
calcd. for C18H26N4O13In; m/z 621, found 621 [(M + H)+], calcd. for C18H24N4O13In; m/z 
619, found 619[(M − H)−]. 115In-DTPA-D-Phe-Asp-OH, calcd. for C27H35N5O14In; m/z 
768, found 768 [(M + H)+], calcd. for C27H33N5O14In; m/z 766, found 766 [(M − H)−] 
 
ddY f8H#ƧƬ,%Þ#ċÚƢġ
 6 Ǘȁ#ǯõ ddY f8H#ÝǳƤ,. D-Phe(1), Asp(0) '$ D-Phe(−1) 
(12 MBq, 0.1 µg, 150 µL) 2åÕǽĕ ·Ĩ"ûz. 24 ĕǦð"7L
]qot¹Ȁǝy _sP5uKǨ×¦ (0.02% NaN3, 1 TIU/mL 5_sNU
t, 2 mmol/L atI5gGtÉǟÉ, 2 mmol/L nuS5JR5gS, 1 mmol/L 
]Oª]9UqiNqHqcUq) 2¸ę/ 0.1 mol/L Tris-@:tǟƓƵń 
(pH 6.5) 2âòÖ-Ŗŀ. ƧƬ2ćð, ǁǽƁSo757H–
i-PrOH-YH",/ôǖƏ Öŋ#Ʋƻ2 3 ½Ɨ.ǒ. ¥Ǔ#ƓƵń 
(2.5 mL) 2ƧƬ"¨
, epRstcjGT7Eu (PT 10-35 <, Kinematica) 
2ţ, ĘǾǖê 30 ŷǦ 3 ½cjGT7Ið, 4 °C  20 Ǧ 
42,000 × g ǚò. xŇ Ĺı2ǰ, 00#ċÚƢ2ŌÔx
Ň&#ċÚƢ#üŞ2ķ*. 
 ', ǆBuGǹƝf8H#ûzŰð- 6 ĕǦð', 6 -
24 ĕǦð'"ăĻ0Þ200Ą².  
 xǓ#đļƹƧƬcjGWuRxŇ,%Ą²Þ2ťÏ
Ǣ 10,000 #ǪË1ǘƪ (Amicon-4) 1ǘð, ǔűHPLC ",.ġ
. ', 0-#ĥ"Ù$, ¢Ǖǅƹ 111In-DTPA-D-Phe-OH, 111In-
DTPA-Asp-OH ,% 111In-DTPA-D-Phe-Asp-OH  ·ĕġ+ÕĒ.  
 !, HPLC ġ$, Ŏń  50 mmol/L ǞǟƓƵń (pH 5.5) ,%
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MeOH 2ţ, y#ĝÕĒ. 
 
Table 10. Condition and RP-HPLC gradient program for radiometabolites analysis. 
 
       • Column: Cosmosil 5C18-AR-II (4.6 × 250 mm) 
       • Flow rate: 0.8 mL/min 




 ñ-0ƏĢ$, éÃ ± ĩōã (SD) Ŵ, ęöãĥÔ"$, Student 


















Ž 3 Ż"ǧ/Õǽ 
 
Ž 3 Ż Ž 1 Ƃ"ǧ/Õǽ 
 
D-Phe(−1) #ƨũŸĤjQqf8H#å 
 Asp(0) #Ç¶ ·Ĩ", AR42J ƌơŸĤð 10–14 ēů#VuSf8H" 
D-Phe(1) '$ D-Phe(−1) (0.1 µg, 5.6 kBq, 100 µL) 2ÝǳƤ,.ûz. û
z 0.5 1, 3, 24 ĕǦð"7L]qot¹ȀǝyòƬ-#ĄƳ",.Ʈ
į, Ƴń,%ǧòƬ¼2Ą²ð"ċÚƢ2ŌÔ. ǩ#Ċ$ 
Asp(0) #ý3f8H#å#ĥƽ ·Ĩ"ƴ. 
 
In vivo ^sO>tAÕǽ 
 ý3f8H" D-Phe(−1) (0.1 µg, 5.6 kBq)  ǴċÚõ octreotide (10 µg) 2
Ņ¶ 20 mmol/L HEPES ƓƵŢŠǷÉĵ (pH 7.4, 100 µL) 2ÝǳƤ,.û
z. ûz 3 ĕǦð"7L]qot¹ȀǝyòƬ-#ĄƳ",.
Ʈį, Ƴń,%ǧòƬ¼2Ą²ð"ċÚƢ2ŌÔ. ǩ#Ċ
$, xƿý3f8H#å#ĥƽ ·Ĩ"ƴ. 
 
D-Phe(−1) ûzð#ý3f8H",/ƧƬ,%ƨũ#ċÚƢġ
 ý3f8H" D-Phe(−1) (12 MBq, 0.1 µg, 150 µL) 2ÝǳƤ,.ûz. 3
,% 24 ĕǦð"7L]qot¹Ȁǝy, _sP5uKǨ×¦ (0.02% 
NaN3, 1 TIU/mL 5_sNUt, 2 mmol/L atI5gGtÉǟÉ, 2 mmol/L nu
S5JR5gS, 1 mmol/L ]Oª]9UqiNqHqcUq) 2¸ę/ 0.1 
mol/L Tris-@:tǟƓƵń (pH 6.5) 2âòÖ-Ŗŀ. ƧƬ,%ƨũ2
ćǩ#Ċ$, ddY f8H#ǆŚġÕǽ ·Ĩ"ƧƬ,%ƨũ
cjGWuR2ǅƹ, Ŏń  50 mmol/L ǞǟƓƵń (pH 5.5) ,%





Table 11. Condition and RP-HPLC gradient program for radiometabolites analysis. 
 
       • Column: Cosmosil 5C18-AR-II (4.6 × 250 mm) 
       • Flow rate: 0.8 mL/min 




Ž 3 Ż Ž 2 Ƃ"ǧ/Õǽ 
 
ƌơ²Ǒ(Õǽ
 12-well plate " AR42J ƌơ2 5.0 × 105 cells ĈŹ, 37 °C, 5% CO2 M
y" 2 ēǦÅǻ. Ž 1 Ż#Õǽ ·Ĩ" 1 pmol # D-Phe(1) '$ 
D-Phe(−1) ŎƻÅÂ (500 µL) 2ņ¨, 5, 10 , 0.5, 1, 2, 4 ĕǦ7t>
lauR. 0.1% Triton-X ¸ę 0.3 mol/L NaOH ĵŎń (1 mL) ƌơ2Ŏ
ƻð, ƌơŎƻń#ċÚƢ,%MtZ@ǋŔê2ŌÔ, ċÚƢ#2
MtZ@ǋǢƸĮ. 
 !, ǴśŨŭ²Ǒ($, 10−6 mol/L #ǴċÚõ octreotide ÑÁy7t>
lauRĕ#ƌơ²Ǒ( , ƌơ2 D-Phe(−1)  7t>lauR
Ǯ"ñ-0ċÚƢ #ã2śŨŭƌơ²Ǒ( . 
 
oG;rJ_Mu5OJ7
 ŌÔ$  5 replicates ÕĒ . MtZ@ǋǢ   20 μg "űî/ 
AR42J ƌơ#ƌơƪøœń  (250 μL) " , 10−12–10−6 mol/L #Ŕê 115In-D-
Phe(1) '$ 115In-D-Phe(−1)   [125I]Tyr11-somatostatin-14 (0.75 kBq) 2Ņ¶, 
30 °C 7t>lauR. ǩ#Ċ$, Ž 1 Ż#Õǽ ·Ĩ"ƴ, 




 12-well plate " AR42J ƌơ2 5.0 × 105 cells ĈŹ, 37 °C, 5% CO2 ĝ
y" 2 ēǦÅǻ. Asp(0) #Ç¶ ·Ĩ", 1 pmol # D-Phe(1) '$ 
D-Phe(−1)  ǴċÚõ octreotide (ƍŔê 10−12–10−6 mol/L) 2·ĕ"ņ¨ 4 
ĕǦ7t>lauRð, 0.1% Triton-X ¸ę 0.3 mol/L NaOH ĵŎń (1 mL) 
ƌơ2Ŏƻ. ñ-0ƌơŎƻń"ċÚƢ,% microBCA ļ
MtZ@ǋŔê2ŌÔ, ċÚƢ#2MtZ@ǋǢƸĮ. 
 ' , 00#ǴċÚõ  octreotide Ŕê",/  D-Phe(1) '$  D-
Phe(−1) #ƌơ²Ǒ2, ǴċÚõ octreotide ǴÑÁy#ƌơ²Ǒ"Ù/ú
¤ţ (%)  ƀ, GraphPad Prism version 7 for Macintosh 2ţǨ×
ėƒ2ƹ IC50 2ƀ. 
 
D-Phe(−1) # in vitro ƨũƌơŏŦõ#ǀ 
 ŌÔ$ 5–6 replicates ÕĒ. 6-well plate " AR42J ƌơ2 1.2 × 106 
cells ĈŹ, 37 °C, 5% CO2 ĝy" 2 ēǦÅǻ. ÅÂ2ǫ¯, 
PBS(−) 2 mL ĿŁð, 0.1% FBS 2¸ę/ Ham’s F-12K ÅÂ (2 mL) 2
ņ¨ , 2 ĕǦ_r7t>lauR . 3 pmol #  D-Phe(1) '$   D-
Phe(−1) ŎƻÅÂ (1 mL) 2ņ¨, 4 ĕǦ7t>lauR. ÅÂ2
ǫ¯ , 10% FBS ¸ę  Ham’s F-12K ÅÂ  (2 mL) ĿŁð , ǴċÚõ 
octreotide (1 µmol/L) Ŏƻ 10% FBS ¸ę Ham’s F-12K ÅÂ 3 mL 2ņ
¨, ê 37 °C, 5% CO2 ĝy7t>lauR. 0, 3, 6, 12  24 
ĕǦð"ÅÂ2ǫ¯, PBS(−) (2 mL) ƌơ2ĿŁð, 0.1% Triton-X ¸ę 0.3 
mol/L NaOH ĵŎń (2 mL) ƌơ2Ŏƻ. ñ-0ƌơŎƻń"
ċÚƢ,% microBCA ļMtZ@ǋŔê2ŌÔ, ċÚƢ#2MtZ
@ǋǢƸĮ. 
 ', 7t>lauRµĕǦ",/ D-Phe(1) '$ D-Phe(−1) #ƌơ
"İÑ/ċÚƢ2, 7t>lauR 0 ĕǦ",/ƌơċÚƢ"Ù




D-Phe(1)   D-Phe(−1) # 37 °C ,% 4 °C ",/ in vitro ƌơ²Ǒ(#
Ĳǎ 
 12-well plate " AR42J ƌơ2 5.0 × 105 cells ĈŹ, 37 °C, 5% CO2 ĝ
y" 2 ēǦÅǻ. ÅÂ2ǫ¯, 37 °C '$ 4 °C # PBS(−) 1 mL 
ĿŁð, Ham’s F-12K ÅÂ (500 µL) 2ņ¨, 37 °C '$ 4 °C   30 
_r7t>lauR. 1 pmol # D-Phe(1) '$  D-Phe(−1) Ŏƻ





 In vivo Õǽñ-0ƏĢ$, éÃ ± ĩōã (SD) Ŵ, in vitro Õ
ǽñ-0ƏĢ$, éÃ ± ĩōǄã (SE) Ŵ.  
 ƌơ²Ǒ(Õǽ",/ęöãĥÔ$, ƐƼL]R  SPSS version 22 
(IBM-SPSS Inc.) 2ţ, ~ǜƘČġ (two-way ANOVA) #ð, Tukey 
#ĥÔ2ÕĒ. 
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hr_, hE¶ »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n¹. 
 
  ]~hE¶, h·¸ Ë	J®WYWYÅ°Y
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